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The immune and coagulation systems are closely linked.  Components of the coagulation 
system, notably activated protein C (APC) and thrombin, have potent effects on the immune 
response.  APC, beyond its traditional function as an anti-coagulant, has broad anti-inflammatory 
effects, mediated through modulation of leukocyte functions and conferring vascular barrier 
protection.  Conversely, thrombin, the central enzyme in coagulation, induces pro-inflammatory 
responses and promotes vascular barrier disruption.  We examined the influences of APC and 
thrombin on the pathogenic components of experimental autoimmune encephalomyelitis (EAE), 
the animal model for multiple sclerosis (MS), an autoimmune disease characterized by 
infiltration of encephalotogenic CD4
+
 T-cells in the CNS resulting in immunopathology. 
We investigated the influence of APC on EAE pathogenesis by inhibiting APC in the 
circulation of mice induced with EAE.  Interestingly, we observed that APC inhibition alleviated 
EAE despite increased blood brain barrier (BBB) permeability and pronounced leukocyte 
infiltration in the brain.  We additionally observed that the encephalotogenic CD4
+
 T-cells in the 
CNS is decreased, and, consistently, the CNS pathology is minimal.  Moreover, inhibition of 
APC modulated the functional responses of peripheral leukocytes, resulting in increased and 
more activated CD11b
+
 myeloid population, including the CD11b
+
 regulatory subset referred to 
  
as myeloid-derived suppressor cells (MDSC) and characterized to be potent T-cell suppressors.  
We demonstrated that the increase in MDSCs resulted in the suppression of functional responses 
of CD4
+
 T-cells required for EAE progression.  Thus, the net effect of APC inhibition during 
EAE is attenuated disease.  
 We additionally examined the inflammatory effects of the coagulation factor, thrombin, 
on an in vitro BBB.  Overall, thrombin effectively modified the BBB, resulting in a BBB 
phenotype that is conducive to leukocyte recruitment, firm adhesion and extravasation.  The 
permissiveness of the BBB to leukocyte transendothelial migration is one the major pathological 
components of EAE and MS.  These findings, therefore, are indicative of thrombin’s potential 
influence on the progression of these diseases.  
 Collectively, the results described in this dissertation strongly demonstrate the capacity 
of APC and thrombin in modulating the pathogenic components of EAE and further affirms that 
the dynamic interactions between the coagulation and immune systems in disease settings can 
affect disease progression.   
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Significance 
A complex and dynamic interaction exist between the immune and coagulation systems.  
Endogenous coagulation components have considerable impact on the pathogenesis of 
inflammatory diseases.  This is demonstrated by the aberrant coagulation states observed in 
severe inflammatory conditions, notably in sepsis [1-3].  Understanding the interplay between 
the immune and coagulation systems, and how this interaction influences the pathogenesis of 
disease conditions will give way to novel therapeutic avenues and provide a more complete 
picture of the underlying biology of disease conditions.  This dissertation describes the influence 
of the endogenous anti-coagulant, activated protein C (APC), on the inflammatory progression 
and pathology of experimental autoimmune encephalomyelitis (EAE), the animal model for 
multiple sclerosis (MS).  In addition, the effect of the coagulation factor, thrombin, on blood 
brain barrier (BBB) permeability, a major pathological component of neuroinflammatory 
diseases, including EAE and MS, is also described.                  
The Coagulation Process 
The coagulation process has traditionally been presented as a cascade of events in which 
coagulation serine proteases activate the factors required for the subsequent step, culminating 
into the formation of a blood clot [4, 5].  This cascade model is divided into two distinct 
pathways, the extrinsic pathway, which is initiated outside the vasculature, and the intrinsic 
pathway, viewed to occur within the vasculature [6, 7].  Both pathways use a common pathway 
to eventually generate the hemostatic plug or blood clot [4-7].  New understanding of 
hemostasis, however, suggests that the cascade model is deficient in accurately depicting the 
coagulation process as it occurs in vivo [6, 7].  In recent years, a new model has been developed 
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that incorporates the importance of cells in hemostasis.  The cell-based model of coagulation 
views the intrinsic and extrinsic pathways not as two separate and redundant pathways but rather 
as parallel pathways that occur on different cell surfaces [6, 7].   
Initiation Phase 
The cell-based model proposes that the initiation phase of the coagulation process in vivo 
occurs on the surface of cells that express tissue factor (TF) [8].  TF is a membrane glycoprotein 
expressed on cells that are normally sequestered from the vasculature, but an injury that results in 
the rupture of blood vessels, such as what occurs in a cut, exposes TF to coagulation factors [6-
8].  The coagulation process is initiated when the active form of the coagulation factor VII 
(FVIIa) binds to exposed TF, and the TF-VIIa complex results in further activation of FVII, thus 
amplifying the number of TF-VIIa complexes [7] (Figure 1.1).  The TF-VIIa complex then 
activates factors IX (FIX) and X (FX) [9].  The activated FX (FXa), that remains bound to the 
surface of TF-expressing cells, can activate Factor V (FVa), which binds to FXa and serve as its 
co-factor [10].  The FXa-FVa complex, also known as prothrombinase complex, remains on the 
surface of TF-bearing cells, where it cleaves prothrombin, generating its active form, thrombin 
[6, 7].     
Amplification Phase    
 The coagulation cascade proceeds to the amplification phase if platelets leak out to the 
extravascular area and adhere to the TF-bearing cells [6, 7].  The small amount of thrombin 
generated on the surface of TF-expressing cells in the initiation phase results in the activation of 
platelets [11] (Figure 1.1).  Activated platelets express negatively charged phospholipids on the 
cell membrane that will bind the glutamic acid (Gla) residues of coagulation proteins [7, 12] .  
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The cell membrane of activated platelets, therefore, provides a pro-coagulant surface on which 
coagulation proteins can localize, thus enhancing the assembly of coagulation complexes and 
amplifying the activation of coagulation factors [6].  
 In addition to platelet activation, the small amount of thrombin generated in the initiation 
phase will result in the activation of factors XI (FXI), FV, and factor VIII (FVIII) [6, 7, 13].  
Thrombin is also responsible for the release of von Willebrand factor from FVIII, thus freeing it 
to mediate platelet adhesion and aggregation [14, 15]. 
Propagation Phase 
 The surfaces of activated platelets serve as the main setting for the propagation phase of 
the coagulation process (Figure 1.1).  FIXa generated both by the TF-VIIa complex in the 
initiation phase and by FXIa in the amplification phase associates with FVIIIa generated during 
the amplification phase to form the tenase complex on the surface of activated platelets [6, 16].  
The tenase complex is responsible for the rapid generation of FXa on platelets [16].  FXa then 
rapidly binds to FVa activated by thrombin in the amplification phase to form additional 
thrombinase complexes on the surface of platelets [17].  The activity of thrombinase complexes 
on platelets leads to a surge of thrombin generation [6, 7].  This burst of thrombin activity results 
in the conversion of fibrinogen to fibrin through the cleavage of fibrinopeptide A from 
fibrinogen [18-20]. This cleavage will reveal polymerization sites that will allow fibrin 
molecules to form soluble complexes with neighboring fibrin and fibrinogen molecules [19, 20].  
A profuse amount of thrombin needs to be generated in order to result in a critical mass of 
soluble fibrin complexes that will spontaneously polymerize into fibrin strands and form an 
insoluble fibrin matrix, which serves as the scaffolding of a blood clot [20].  
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            Figure 1.1 The cell-based model of the coagulation process. 
    
Tissue factor 
Bearing cell
Endothelial Cell Endothelial Cell
Tissue factor
bearing cell
Tissue factor 
bearing cell
Tissue factor
bearing cell
Tissue Factor
FVIIa
FXa
FVa
Tissue Factor
Thrombin
Tissue FactorTissue Factor
FXIa
FVa
Activated
Platelet FVIIIa
FIXa
FVIIIa
FXaFVa
Thrombin
Thrombin
Thrombin
P
ro
p
a
g
a
ti
o
n
 P
h
a
se
A
m
p
li
fi
c
a
ti
o
n
 P
h
a
se
Fibrin Formation
In
it
ia
ti
o
n
 P
h
a
se
 
6 
 
The Protein C Anti-Coagulant System 
The coagulation process is tightly regulated in order to localize the coagulation cascade 
in the area of injury and prevent systemic dissemination of activated coagulation proteins that 
may lead to thrombosis [21].  The protein C anti-coagulant pathway is one of several systems 
that regulate the coagulation process.  The initiation of the protein C pathway occurs when 
thrombin binds to thrombomodulin, a transmembrane glycoprotein on the surface of endothelial 
cells [22] (Figure 1.2).  This binding blocks thrombin’s exosite I, a site required for thrombin’s 
interactions with its substrates in the coagulation cascade, thus effectively abrogating thrombin’s 
pro-coagulant activity [23].  Once thrombin is complexed to thrombomodulin, its substrate 
affinity is switched to the zymogen, protein C (PC), resulting in the cleavage of the activation 
peptide of PC to generate the serine protease, activated protein C (APC) [24].  The activation of 
PC is enhanced if PC is bound to the endothelial protein C receptor (EPCR), which co-localizates 
PC with the thrombin-thrombomodulin complex on the surface of endothelial cells [25].  APC 
regulates the coagulation process by proteolytically inactivating FVa and FVIIIa, thus inhibiting 
further generation of thrombin and consequently dampening the coagulation cascade [26, 27].  
Protein S, a vitamin K-dependent glycoprotein, acts as a co-factor for APC in the inactivation of 
FVa and FVIIIa [28, 29].        
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Figure 1.2 The Activated Protein C anti-coagulant pathway. 
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Two-way interaction between the Coagulation and Immune Systems 
The existence of a link between the coagulation and immune systems is manifested in the 
aberrant coagulation state observed in severe inflammatory conditions [30, 31].  This is notably 
true in sepsis wherein coagulopathy is considered one of the pathologic hallmarks of the disease 
[2].  The activation of the coagulation process in sepsis is evidenced by fibrin deposition in blood 
vessels and various organs [1, 3].  Septic patients also exhibit low platelet counts and increased 
risk of bleeding, as a result of rapid consumption of platelets and coagulation factors [1].  
Moreover, disseminated intravascular coagulation (DIC) correlates with sepsis severity and 
considered a predictor of organ failure and mortality in septic patients [1, 3].  Induction of the 
coagulation system has also been observed in inflammatory conditions caused by viral, fungal, 
protozoan, and spirochetes infection [32-35].  A number of autoimmune disorders, including 
inflammatory bowel disease, systemic lupus erythematosus, rheumatoid arthritis, and type-1 
diabetes mellitus, have also been associated with abnormal coagulation conditions [36-39].    
 
Initiation of the Coagulation Process and Inhibition of Anti-coagulant Pathways during 
Inflammatory Conditions 
 There is a consensus understanding that the activation of the coagulation process during 
severe inflammatory conditions is largely mediated by pro-inflammatory cytokines [40].   As 
outlined above, the coagulation process is initiated in vivo through exposure of coagulation 
components to TF, which is normally expressed on cells outside the vasculature.  In 
inflammatory settings, the production of pro-inflammatory cytokines, particularly IL-6, results in 
the induced expression of TF on circulating mononuclear cells and on endothelial cells, 
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consequently leading to activation of the coagulation cascade [30].  The central role of IL-6 and 
TF in the initiation of the coagulation process in inflammatory setting have been demonstrated in 
a number of studies in which inhibition of either IL-6 or TF during pro-inflammatory conditions, 
such as in endotoxemia, abrogates the activation of the coagulation cascade and alleviates 
disease pathology [41, 42]. 
 While inflammatory conditions results in the activation of the coagulation process, the 
anti-coagulant pathways, conversely, are actively suppressed during inflammation [43].  Levels 
of APC in the circulation during inflammatory settings are diminished due to decreased synthesis 
of PC in the liver and inhibited PC activation [43].  Pro-inflammatory cytokines, specifically 
TNF-α, down-regulate the expression of thrombomodulin and EPCR on the endothelium [44, 
45], both of which are required for the effective activation of PC [22], thus resulting in deficient 
PC activation and an overall impaired protein C pathway. 
 
How Thrombin Influences the Inflammatory Response 
 The cross-talk between the coagulation and immune systems is a two-way interaction, 
wherein both systems impact each other [46].  Accordingly, the activation of the coagulation 
system during inflammatory conditions results in the generation of coagulant factors that can 
directly affect the immune response [40].  In particular, thrombin, beyond its role as the central 
protease in the coagulation cascade, has considerable and well-documented impact on several 
aspects of the immune response [47].  The overall influence of thrombin on the immune system 
is to propagate inflammation, and this is mediated through thrombin’s capability to activate a 
group of G-protein-coupled cellular receptors known as protease-activated receptors (PARs) [47-
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49].  There are four identified PARs, namely PAR-1, PAR-2, PAR-3, and PAR-4; thrombin is 
known to activate PARs 1, 3, and 4 [48, 49].  Thrombin activation of PARs requires proteolytic 
cleavage of the N-terminal part of a tethered ligand on the extracellular domain of the receptor, 
consequently exposing a new N-terminus sequence that can associate with the extracellular loop 
2 of the receptor to initiate cell signaling [48, 50].  Various cell types, including endothelial cells, 
fibroblasts, platelets, smooth muscle cells and several leukocyte populations express PARs, 
enabling thrombin to directly regulate the cellular processes and responses of these cells [30].  
Thrombin propagates inflammation largely through its ability to direct cell signaling in 
endothelial cells and several leukocyte subsets [47].   
Thrombin activation of PARs, specifically PAR-1, expressed on the endothelium induces 
endothelial cells to undergo phenotypic changes that include cytoskeletal rearrangements, 
alterations in cell shape, and disassembly of junctional proteins, leading to an overall increase in 
vascular permeability [47, 51, 52].  Downstream signaling of thrombin-activated PAR-1 on 
endothelial cells involves PAR-1 coupling with G proteins, Gαq and Gα12/13 [53] (Figure 1.3).  
Thrombin-activated PAR-1 additionally results in the trans-activation of sphingosine 1-
phosphate receptor 3 (S1P3) [47] (Figure 1.3).  S1P3 is one of five G-protein-coupled receptors 
for the lipid derivative, sphingosine 1-phosphate (SIP) [47, 54].  Similar to PAR-1, activated 
S1P3 also couples with Gαq and Gα12/13 [47, 54].  Coupling of PAR-1 and S1P3 to these particular 
G-proteins results in the stimulation of the guanosine triphosphatase (GTPase), RhoA, which 
mediates cytoskeletal re-organization and disassembly of the junctional proteins that connect 
adjacent endothelial cells, consequently increasing vascular barrier permeability [47, 54].  
Thrombin has also been reported to modulate the transcription of a wide spectrum of genes in 
endothelial cells, notably increasing the expression of molecules that can facilitate trafficking 
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and leukocyte-adhesion to the endothelium [50]; these include increased expression of adhesion 
molecules, ICAM-1, VCAM-1 [55], and increased generation of chemokines, IL-8 and MCP-1 
[56, 57].  It follows that the cumulative effect of thrombin on the endothelium during 
inflammatory conditions is increased vascular permeability to leukocyte transendothelial 
migration.   In fact, it has been shown that direct inhibition of thrombin in an inflammatory 
setting impedes leukocyte adhesion to the endothelium and vascular leakage in vivo [58].  PAR-1 
antagonism similarly inhibited in vivo leukocyte recruitment [59].  
Thrombin additionally exerts its pro-inflammatory effects by directly modulating 
leukocyte function (Figure.1.3).  The expression of PAR-1 has been observed on monocytes, 
macrophages, dendritic cells, and T-cells [60-63].  Thrombin can induce chemotaxis in 
monocytes and elicit the production of IL-6 and MCP-1 [64-66].  The proliferative responses and 
cytokine production in T-cells are augmented as a result of thrombin activation [67].  Thrombin-
mediated signaling in dendritic cells (DC) regulates the production of cytokines and enhances the 
antigen presenting capacity in these cells [62].  Moreover, the PAR-1 and S1P3 signaling 
pathway in DCs has been implicated in the dissemination of inflammation in an animal model of 
sepsis [68].   
Consistently, a number of studies in animal models of inflammation have demonstrated 
that modulation of thrombin levels and thrombin-associated signaling can reduce systemic 
inflammation and disease pathology.  For instance, in baboons lethally challenged with 
Escherichia coli, treatment with recombinant human antithrombin III, an endogenous thrombin 
inhibitor, attenuated inflammation and improved survival [69].  Thrombin inhibition and 
selective PAR-1 antagonism similarly improved survival in mice challenged with 
lipopolysaccharide (LPS) [68]. 
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         Figure1.3. Thrombin and APC have opposing influences on endothelial cells and                                   
 leukocytes. 
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How APC influences the Inflammatory Response 
 In much the same way that APC and thrombin are functionally opposite in their 
respective roles in the coagulation process, their overall influence on the immune response are 
similarly divergent.  Whereas thrombin has primarily been associated with pro-inflammatory 
responses, APC, in contrast, has potent anti-inflammatory and anti-apoptotic effects [23].  Both 
APC and thrombin, however, mirror each other in the way they exert their influence on the 
immune response, which is primarily through their cell-signaling capacities that enable both 
molecules to  directly regulate cellular functions [70].  Moreover, in somewhat of a paradoxical 
twist, APC and thrombin invoke opposing influences on the immune response through activation 
of the same cellular receptor, PAR-1 [71, 72] (Figure 1.3).  APC, however, needs to bind to 
EPCR in order to initiate signaling through PAR-1 [72], and it has been proposed that APC’s 
occupancy of EPCR is the mediating factor that enables APC and thrombin to initiate divergent 
and opposing cellular responses from one receptor [73-75] (Figure 1.3).  One group has 
suggested that the association of APC to EPCR localizes APC in the cholesterol-enriched lipid 
rafts or caveolae microdomains of the cell membrane, where PAR-1 and EPCR are both co-
localized [74, 75].  They propose that the binding of APC to EPCR may induce changes in the 
membrane localization and/or conformation of the PAR-1 exodomain that renders PAR-1 more 
accessible to activation [75].  Furthermore, it was demonstrated that the binding of APC to 
EPCR results in the migration of EPCR from the caveolar compartment, a process that appears to 
induce PAR-1 to switch its G-protein association to Gi, subsequently triggering cell signaling 
cascades that favor anti-inflammatory responses [73, 75].  This deviates from thrombin 
activation of PAR-1, which results in PAR-1 coupling to Gαq and Gα12/13, thereby giving rise to 
pro-inflammatory processes [54]. 
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 The anti-inflammatory influences of APC are primarily mediated through its direct ability 
to regulate the cellular responses in endothelial cells and leukocytes [23].  The culminating effect 
of APC on the endothelium during inflammatory conditions is to limit the extravasation of 
inflammatory leukocytes into tissues [23].  This is a direct result of APC’s potent ability to 
stabilize the integrity of the endothelial barrier.  As noted above, most of the cell signaling 
pathways mediated by APC, including its barrier protective effects, involves the coupling of 
PAR-1 to the G protein, Gi.  APC- mediated signaling in endothelial cells also results in the 
transactivation of S1P1, one of the receptors for the sphingolipid, S1P, that couples with Gi [54, 
76].  This is in contrast to thrombin-mediated signaling, which transactivates the S1P3 receptor, 
resulting in mobilization of the second messenger, RhoA, known to facilitate endothelial barrier 
disruption.  S1P1 transactivation by APC, on the other hand, mobilizes the second messenger, 
Rac1, needed for the stabilization of cytoskeletal elements, thereby conferring vascular barrier 
protection [77, 78].  APC is also known to modulate the expression of transcription factors and 
various genes in endothelial cells.  In TNF-α-treated endothelial cells, APC was shown to 
counter-suppress genes that were up-regulated by TNF-α [79].  These include down-regulation of 
the expression levels of adhesion molecules, ICAM-1, VCAM-1, and E-selectin, likely through 
APC’s regulation of the NFκB signaling pathway [79].  APC can reduce the mRNA expression 
of the p52 subunit of the transcription factor, NFκB, in endothelial cells [79]. 
 A number of studies have demonstrated that APC can directly regulate the inflammatory 
responses of various leukocyte populations.  In monocytes stimulated with pro-inflammatory 
factors such as LPS and IFN-γ, APC can inhibit the production of TNF-α, IL-1β, IL-6, and IL-8 
[80, 81].  APC has also been shown to decrease the generation of pro-inflammatory mediators in 
macrophages [81, 82].  One study has demonstrated that APC can reduce the mortality in a 
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mouse model of sepsis through down-regulation of inflammatory responses in DCs [83].  The 
ability of APC to down-regulate the generation of pro-inflammatory factors in leukocytes have 
been attributed to APC’s capability to regulate several inflammatory signaling pathways, notably 
the NFκB pathway [84, 85].  One study has demonstrated that APC can similarly modulate the 
Wnt signaling pathway in macrophages [86].  It is, however, still unclear as to which cellular 
receptors are involved in the APC-mediated signaling in leukocytes.  Some have implicated the 
EPCR/PAR-1 receptors [80, 87]; while other studies have demonstrated that the regulatory 
effects of APC on leukocytes are not dependent on EPCR [88, 89].  One study, in particular, has 
shown that APC’s anti-inflammatory effects on macrophages are mediated through the 
association of APC to the CD11b integrin and subsequent PAR-1 activation but do not involve 
EPCR [90].   
 Beyond mediating anti-inflammatory responses, APC has also been reported to inhibit 
cellular apoptosis [23].  APC can down-regulate key regulators involved in the intrinsic and 
extrinsic apoptotic pathway.  APC has been shown to decrease the expression of the tumor-
suppressor protein, p53, a central protein in the intrinsic apoptotic pathway [91].  Similarly APC 
can modulate the extrinsic apoptotic pathway by inhibiting the activation of caspase 8 [92]. 
 APC’s potent anti-inflammatory and anti-apoptotic effects are reflected on its ability to 
attenuate inflammation and pathology in various disease settings.  APC’s efficacy as a 
therapeutic molecule in a human inflammatory disease setting was demonstrated in the 
PROWESS study, a breakthrough phase III clinical trial, wherein infusion of recombinant APC 
in patients with severe sepsis reduced mortality [93].   Utilizing APC in the treatment of sepsis, 
however, remains controversial since the efficacy of APC was not consistently demonstrated in 
subsequent clinical trials [94, 95].  In other disease settings, APC has also been reported to 
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strongly influence disease pathology.  For instance, in animal models for lung injury and 
inflammation, APC has been shown to be protective by inhibiting leukocyte accumulation and 
chemotaxis [96, 97].  Similarly in murine models for cerebral ischemia and stroke, APC has been 
demonstrated to increase survival through its potent anti-inflammatory and neuroprotective 
effects [98, 99].  APC’s neuroprotective effect in stroke models has been attributed to its ability 
to inhibit neuronal apoptosis by regulating the p53 apoptotic pathway [91].  Other disease 
models in which APC has been shown to confer protection include inflammatory bowel disease 
(IBD)[100], diabetes [101], and amyotrophic lateral sclerosis (ALS) [102]. 
 
Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis 
Multiple Sclerosis 
 Multiple Sclerosis (MS) is a complex neurologic disease with diverse clinical and 
pathological symptoms.  The hallmark pathogenesis of the remitting/relapsing phase, which 
constitutes the initial stage of MS, is characterized by the formation of focal demyelinated 
lesions in the white matter of the central nervous system (CNS) [103, 104].   As the disease 
enters the progressive phase, the pathogenesis in the CNS becomes more widespread, involving 
axonal pathology and neurodegeneration, both in the white and grey matter [103, 105].  Among 
the clinical symptoms manifested by MS patients include cognitive deficiencies, coordination 
and balance problems, and in the most severe form, paralysis [106-108].  It is believed that MS 
can develop because of genetic susceptibility, and some have proposed that outside 
environmental factors, such as a viral infection, may also trigger the disease [109-111]. 
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  It is widely accepted that the driving force behind the CNS pathology in MS is an 
inflammatory process, primarily mediated by autoreactive T lymphocytes (T-cells) specific for 
neuroantigens [109].   Demyelination in MS lesions is believed to be largely mediated by 
infiltrating T-cells and activated microglial cells [108-110].  Human Leukocyte Antigen (HLA) 
Class II-restricted CD4
+
 T-cells have been specifically implicated in the initial formation of 
lesions [109].  The involvement of CD4
+
 T-cells in MS is evidenced by the strong association of 
HLA class II genes with genetic susceptibility for MS [111].  Acute lesions are known to be 
initiated by IFNγ-producing CD4+ T helper type I (TH1) cells [109].  The pathogenic CD4+ T 
helper 17 (TH17) subset has similarly been highly implicated in MS immunopathology [108].  
The mRNA expression of IL-17, the signature cytokine produced by Th17 cells, is increased in 
the mononuclear cells in the cerebrospinal fluid (CFS) of MS patients [112, 113].  The 
production of IL-17 and IFN-γ by infiltrating CD4+ T-cells induces the activation of resident 
cells in the CNS, notably microglial cells, which is known to generate inflammatory factors such 
as nitric oxide (NO) that can mediate demyelination and axonal pathology [108, 110].  While 
TH1 and TH17 cells are known to be pathogenic in MS, the CD4
+
 T-regulatory (T-regs) subset 
and the T-helper 2 (TH2), conversely, inhibit disease progression [114].  T-regs are reportedly 
impaired in patients with MS [115].  The importance of CD4
+
 T-cells in MS initiation and 
progression is well-established; it should be noted, however, that Class-I restricted CD8
+
 T-cells 
are also found in large numbers in MS lesions, suggesting their equally likely significance in MS 
pathology [116].  In addition to these cellular components, evidence of blood brain barrier (BBB) 
damage has also been observed both in MS active lesions and inactive plaques [109, 110].  The 
production of IL-17 has been specifically implicated in increased BBB dysfunction and the 
further recruitment and extravasation of peripheral leukocytes to the CNS [108]. 
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 Several pharmacological treatments were developed and approved for MS therapy.  IFNβ 
treatment is one of the longest approved and more-widely used therapies for relapsing-remitting 
MS [117].  IFNβ acts on type-1 IFN transmembrane receptors to initiate signaling cascades that 
can directly mediate T-cell function [117].  IFNβ is known to limit T-cell activation and 
proliferation [118].  Moreover, IFNβ is also believed to limit T-cell extravasation into the CNS 
by downregulating several molecules, such as VLA-4, which is involved in T-cell adhesion to 
the BBB [117].  Another long-time used MS treatment is glatiramer acetate (GA), a synthetic 
polymer resembling myelin basic protein (MBP), a component of myelin [117].  GA interferes 
with the activation of myelin-specific T-cells by binding directly to MHC II on antigen 
presenting cells [119].  It also believed that myelin-T cells exposed to GA results in the decrease 
of IFN-γ production and skews the immune response to TH2 [117].         
Experimental Autoimmune Encephalomyelitis  
 Most of what is currently known about the immunopathology of MS and the development 
of disease treatments are derived from studies utilizing the animal models of the disease [120].  
Experimental autoimmune encephalomyelitis (EAE), the most widely studied model for MS, 
closely replicates the immunologic and pathologic characteristics of MS [121].  EAE can be 
induced in various animals; however, in recent years, the murine EAE model has been the most 
commonly utilized [121].  EAE is induced through the immunization of CNS antigens or through 
the passive transfer of encephalitogenic T-cells [120, 121].  Immunization with neuroantigens 
typically requires the antigens to be emulsified in an adjuvant [120, 121].  Several EAE models 
co-administer pertussis toxin (PTX) to increase disease severity; PTX is known to increase BBB 
permeability, thus facilitating the entry of autoreactive lymphocytes into the CNS [122, 123].  
The clinical course of the disease is dependent on the mouse strain and the combination of 
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neuroantigen and adjuvant used [121].  Immunization with the myelin peptide, myelin 
oligodendrocyte glycoprotein peptide35-55 (MOG35-55) in C57BL/6 mice results in a monophasic, 
chronic disease, with immune cell infiltration and pathology in the spinal cord and the brain 
[124].  Immunization with myelin proteolipid protein (PLP) in SJL mice results in chronic 
relapsing disease [125].  Neuroantigens are typically emulsified in Complete Freud’s Adjuvant 
(CFA), the most commonly used adjuvant in EAE models, resulting in the induction of TH1 and 
TH17 immune response [126].  The immunopathology in EAE has been strongly attributed to 
both these CD4
+
 subsets; and this is consistent with the fact that TH1 and TH17 cells have been 
detected in MS lesions and in the cerebrospinal fluid (CSF) of MS patients [114].  In EAE, it 
appears that a combination of both TH1 and TH17 is required for disease development.  It has 
been demonstrated, for instance, that mice lacking the TH17 subset but with intact TH1 response 
fail to develop EAE [127].  Other CD4
+ 
subsets, specifically, TH2 and T-reg cells, are non-
pathogenic in EAE [114].  T-reg cells, in fact, actively confer protection in EAE by inhibiting 
autoreactive T-cells, likely through cell-to cell contact mechanisms and/or the production of anti-
inflammatory factors such as IL-10 and TGF-β [128].    It should be noted that while CD4
+ 
T-
cells are generally regarded as the main effectors cells in EAE and MS, other lymphocytes such 
as CD8
+
 T-cells and B cells have been demonstrated to also cause immunopathology in the EAE 
disease setting [114]. 
 Within the first five days after EAE immunization, neuroantigen-specific T-cells are 
activated and proliferate in secondary lymphoid organs.  As early as day 5 post immunization, 
activated T-cells disseminate systemically, and a number of activated T-cells transmigrate across 
the BBB and enter the CNS [129].  It has been proposed that activated T-cells, regardless of 
specificity, can transmigrate through the BBB and enter the CNS; if these cells do not encounter 
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their antigen in the CNS, however, the cells return to the circulation [130].  In the EAE model, 
CNS barriers, including the BBB and the epithelial barriers within the choroid plexus, are more 
permeable to immune cells as a result of pertussis toxin administration and pro-inflammatory 
factors produced by activated lymphocytes, thus facilitating the entry of neuroantigen-specific T-
cells [130].  Once neuroantigen-specific T-cells encounter their antigen in the CNS, they are 
stimulated to produce cytokines that not only result in the further recruitment of inflammatory 
leukocytes from the periphery but also results in the recruitment and activation of resident cells 
in the CNS, notably microglial cells [131].  Neuroantigen-specific CD4
+
 TH1 cells that 
transmigrate to the CNS produce IFN-γ resulting in the induction of microglial cells to produce 
inflammatory factors, such as nitric oxide (NO), oxygen radicals, and TNF-α, which are toxic to 
oligodendrocytes thus promoting these cells to undergo apoptosis [132].   Oligodendroctyes are 
glial cells that associate with neuronal axons and produce the myelin sheath that encloses the 
axon [132].  In EAE and MS, oligodendrocyte cell death, as a result of inflammation, greatly 
contribute to the demyelinating pathology [132].  Moreover, the pro-inflammatory factors 
produced by activated microglial cells also result in axonal pathology and neurodegeneration 
[114].  CD4+ TH17 cells that are activated by neuroantigens in the CNS produce IL-17, which 
similarly promote microglial activation [131].  Furthermore, generation of IL-17 in the CNS has 
also been attributed to increased BBB disruption and enhanced recruitment of peripheral 
leukocytes, notably neutrophils, resulting in the sustainment of CNS inflammation and further 
immune pathology [108].  While CD4
+ 
T-cells are sufficient to induce disease and mediate CNS 
pathology, as demonstrated by adoptive transfer studies involving CD4
+ 
T-cells, other 
lymphocyte populations are also believed to contribute to EAE and MS pathology.  CD8
+
 T-
cells, in particular, which have been observed to constitute a majority of the infiltrating cellular 
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components in MS lesions, have been implicated in axonal pathology and neurodegeneration in 
EAE models [114].           
 
Coagulation Factors in Experimental Autoimmune Encephalomyelitis and Multiple 
Sclerosis 
 While the functions of endogenous coagulation proteins, such as APC and thrombin, in 
the progression and pathogenesis of EAE and MS have yet to be clearly delineated, there are 
accumulating studies suggesting the likely involvement of the endogenous coagulation system in 
EAE and MS pathology.  Proteomics analysis of MS lesions revealed the presence of coagulation 
proteins in chronic active plaques [133].  In particular, protein C inhibitor, which is known to 
inhibit APC, was one of coagulation proteins detected in MS plaques [133].  Studies on the EAE 
model show elevated levels of thrombin inhibitors detected both in the periphery and the CNS 
[134, 135].  Fibrin deposition has also been observed in the brains of EAE rodents [136].  The 
findings of these studies strongly suggest the possible activation of coagulation components 
during the progression of EAE and MS.  The effects of coagulation factors on specific aspects of 
MS and EAE pathogenesis will need to be determined.  The likely influence of coagulation 
proteins, particularly, APC and thrombin, on the pathology of neuroinflammatory diseases is 
potentiated by the ability of both proteins to directly affect resident cells in the CNS.  APC, for 
instance, has been demonstrated to be neuroprotective by downregulating apoptotic pathways in 
neurons during pathological conditions [91].  Moreover, glial cells express PAR-1 [137], which 
is indicative of receptiveness to thrombin or APC regulation.  Thrombin, in fact, has been 
reported to regulate microglial generation of pro-inflammatory factors and astrocyte activation 
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[137, 138].   Thus in addition to thrombin and APC’s effects on traditional cellular components 
of the immune system, these coagulation proteins may also influence the disease progression of 
EAE and MS through the capacity to mediate the cellular responses of resident cells in the CNS.  
Finally, it should be noted that one of the major pathological components of both EAE and MS is 
BBB dysfunction, which further underscores the likely relevance of APC and thrombin in 
disease progression, given APC’s ability to confer vascular barrier protection and thrombin’s 
promotion of vascular barrier disruption.     
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Synthesis 
 The studies presented in this dissertation describe the effects of coagulation factors, APC 
and thrombin on pathogenic components of EAE.  In Chapter 2, we demonstrate the influence 
of APC inhibition on EAE pathogenesis and disease progression.  We show that abrogation of 
APC activity in the systemic circulation increased BBB permeability, resulting in pronounced 
leukocyte infiltrates in the brains of EAE mice.  However, despite the presence of considerable 
infiltrates, these mice exhibited minimal CNS pathology and attenuated disease.  Moreover, we 
show that inhibition of APC activity modulated the functional responses of specific leukocyte 
populations, resulting in increased and more activated CD11b
+
 myeloid cells.  Among the 
CD11b
+
 population that expanded as a result of APC inhibition are myeloid-derived suppressor 
cells (MDSC), characterized to be potent T-cell suppressors.  We demonstrate that the increase in 
MDSCs resulted in a deficient and defective CD4
+
 T-cell population, consequently attenuating 
EAE progression. 
 In Chapter 3, we demonstrate that thrombin effectively induced an inflammatory 
phenotype in the BBB, which plays a prominent role in EAE and MS pathology.  We show that 
thrombin activated the BBB, resulting in increased expression of adhesion molecules and various 
chemokines.  Furthermore, thrombin additionally elevated the paracellular permeability of the 
BBB in vitro.  Overall, this study demonstrated that thrombin effectively induced the BBB to 
adopt a phenotype that can potentially facilitate the recruitment, firm adhesion, and diapedesis of 
leukocytes, suggesting thrombin’s relevance in neuroinflammatory conditions such as EAE and 
MS. 
 We summarize our findings in Chapter 4.  We additionally present our conclusions and 
suggest future directions.      
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CHAPTER 2 
Inhibition of endogenous activated protein C attenuates 
experimental autoimmune encephalomyelitis by inducing 
myeloid-derived suppressor cells 
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Abstract 
 
Activated protein C (APC) is an anti-coagulant involved in the interactions between the 
coagulation and immune systems.  APC has broad anti-inflammatory effects mediated through 
its capability to modulate leukocyte function and confer vascular barrier protection.  In this 
study, we investigated the influence of APC on the pathogenesis of experimental autoimmune 
encephalomyelitis (EAE), the animal model for multiple sclerosis. We modulated APC levels in 
the circulation during the induction of EAE through systemic administration of a monoclonal 
antibody against protein C/APC (anti-PC).  We hypothesized that inhibition of APC may result 
in a heightened inflammatory environment thereby resulting in increased EAE pathogenesis.  On 
the contrary, we observed that mice treated with anti-PC antibody (anti-PC mice) exhibited 
attenuated clinical signs of EAE.   Most striking is that despite attenuated EAE symptoms, anti-
PC mice exhibited considerable leukocyte infiltration in the brain, comparable to control mice 
with very severe EAE.   We show that attenuated EAE in anti-PC mice is a consequence of the 
induction of a recently-described CD11b
+
 population, referred to as myeloid-derived suppressor 
cells (MDSC) and characterized to be potent suppressors of effector T-cell function.  We 
conclude that inhibition of APC can affect the functional responses of CD11b
+
 cells, resulting in 
expansion and increased activation of MDSCs, consequently suppressing T-cell function and 
attenuating EAE.  These findings present a novel influence of APC on the immune response and 
contribute to further elucidating the complex interaction between the immune and coagulation 
systems. 
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Introduction 
The anti-coagulant, APC, has a prominent role in mediating the complex crosstalk 
between the coagulation and inflammatory responses [1-3].  APC is a serine protease derived 
from the zymogen protein C (PC), which is activated on the surface of endothelial cells by the 
coagulation factor, thrombin bound to the glycoprotein, thrombomodulin [3].  Once activated, 
APC in the circulation is known for regulating blood clotting through its ability to proteolytically 
inactivate coagulation factors Va and VIIIa, consequently dampening further generation of 
thrombin [4].  Independent of APC’s function in the coagulation cascade, APC can affect various 
cellular processes through its interactions with membrane receptors.  APC mediates cell 
signaling in endothelial cells through binding with endothelial protein C receptor (EPCR), 
enabling APC to activate the G-protein coupled receptor, protease-activated receptor-1 (PAR-1) 
[5, 6].  APC-mediated activation of PAR-1 on endothelial cells reduces endothelial permeability 
through stabilization of cytoskeletal components [7], consequently limiting the extravasation of 
inflammatory leukocytes [5].  APC additionally directs leukocyte function through alteration of 
signaling pathways involved in inflammatory responses [8-12].  Several studies have proposed 
that APC’s effects on leukocytes may similarly be mediated through the EPCR/PAR-1 pathway 
[13, 14].  However, a more recent study has shown that APC’s anti-inflammatory effects on 
myeloid cells are mediated through the binding of APC to the CD11b integrin [15].  
The pleiotropic effects of APC, which encompasses both cell signaling and anti-
coagulant properties, are indicative of its influence in various disease conditions and its potential 
as a promising therapeutic target.  The efficacy of APC as a therapeutic molecule has, in fact, 
already been demonstrated for severe sepsis.  In the PROWESS study, infusion of human 
recombinant APC improved survival among patients with severe sepsis [16].  The effectiveness 
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of APC in sepsis treatment however remains controversial since its efficacy was not exhibited in 
a subsequent trial [17], prompting the withdrawal of the drug from the market [18].  
Nevertheless, APC’s protective effects in other disease settings have been evidenced in various 
animal studies.  In ischemic stroke models, APC can reduce leukocyte infiltration in the brain 
[19], and APC can ameliorate the animal model for amyotrophic lateral sclerosis (ALS) by 
conferring blood-spinal cord barrier protection [20].  APC has also been demonstrated to 
attenuate inflammation in mouse models for inflammatory bowel disease (IBD) [21] and lung 
injury model [22].   
In this study, we set out to investigate the influence of endogenous APC on the 
pathogenesis of EAE, the animal model for multiple sclerosis (MS).  EAE and MS are 
autoimmune disorders characterized by neuroinflammation and consequent axonal demyelination 
leading to clinical symptoms such as paralysis [23, 24].  The neuroinflammatory response in 
EAE is mainly mediated by effector CD4
+
 T-cells that are able to infiltrate the central nervous 
system (CNS) as a result of permeability and dysfunction at CNS barriers [25].  Our rationale for 
studying APC in EAE stems from previous studies suggesting the likely involvement of 
endogenous coagulation components in EAE and MS pathology.  In a study by Han et. al, 
proteomics analysis of MS lesions revealed the presence of coagulation proteins in chronic active 
plaques [26].  In EAE studies, fibrin deposition in the brain has been reported [27], and increased 
presence of thrombin inhibitors were detected in the peripheral circulation of EAE mice [28].  
Moreover, APC’s known anti-inflammatory effects, specifically its ability to mediate leukocyte 
function and confer vascular barrier protection, further underscore the relevance of studying 
APC in EAE, wherein the major pathological component is CNS barrier dysfunction resulting in 
neuroinflammation and pathology. 
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To investigate APC function in EAE, we inhibited endogenous APC during disease 
progression through systemic administration of an antibody against protein C/APC (anti-PC).  
We anticipated that blocking APC may lead to worsening of EAE due to CNS barrier 
dysfunction and/or by exacerbating systemic inflammation.  Converse to our hypothesis, we 
observed that mice treated with anti-PC exhibited attenuated clinical symptoms despite 
considerable leukocyte infiltration in the brain.  Moreover, we observed diminished T-cell 
effector function in these mice, coupled with increased expansion of MDSCs, a cell-subset 
characterized to be potent  T-cell supressors [29].   This study shows that diminished APC 
activity can affect EAE pathogenesis at multiple fronts, influencing both BBB permeability and 
effector functions of leukocytes.  The results of this study exemplify the intricate and multi-
faceted interaction between the coagulation and immune systems, which is likely further 
complicated by each unique disease setting.  
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Materials and Methods 
Mice:  C57BL/6 (BL/6) mice and C57BL/6 2d2 TCR transgenic mice were generated from our 
in-house breeding colony or were purchased from Taconic (Germantown).  Mice were 
maintained in specific pathogen-free facility at Cornell University.  Procedures performed on 
mice were approved by the Institutional Animal Care and Use Committee of Cornell University. 
EAE induction:  To induce EAE, a 1:1 emulsion of myelin oligodendrocyte glycoprotein 
peptide (MOG35-55) (Anaspec) at 1 mg/ml and complete Freund’s adjuvant (CFA) (Sigma) was 
subcutaneously injected into mice flanks.  Pertussis toxin (PTX) (List Biologicals) at 20 ng/ml 
was intravenously injected on the day of immunization, and a second dose was administered 48 
hours later.  Disease severity was assessed daily, and clinical scores were assigned as follows: 0 
= no disease, 0.5 = weak tail, 1 = completely limp tail, 1.5 = impaired righting reflex, 2 = 
affected gait, 2.5 = partial hind limb paralysis, 3 = complete hind limb paralysis, 3.5 =  hind limb 
and partial forelimb paralysis, 4 = moribund, 5 = death.  Mice that reach a score of 4 are 
euthanized and scored as 5.   
Antibody to protein C:  Generation of mAb MPC1609 (anti-PC) was described previously [30]. 
Anti-PC was raised to mouse PC and cross reacts with mouse APC.  Anti-PC inhibits the 
activation of protein C and blocks both PC and APC from binding to endothelium and 
phospholipid surfaces, thus effectively abrogating APC’s anticoagulant and cell signaling 
capabilities [30].  The antibody at 1mg/kg was administered via intraperitoneal (i.p) injection. 
 Immunohistochemistry:  CNS harvested after perfusion were snap frozen in OCT media 
(Tissue-Tek, CA).  Frozen tissues were sectioned to 6-micron thickness using a cryostat, and 
sections were affixed to Superfrost Plus slides (Fisher).  After fixing in acetone, slides were 
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washed in PBS and blocked with casein (Vector Labs) for 10 minutes.  Slides were then 
incubated with primary antibodies for 90 minutes at 37
o
C.  Primary antibodies used are as 
follows: anti-CD45 (AbD Serotec) anti-Iba-1 (Wako Chemicals), anti-MOG (R&D Systems).  
After washing, slides were incubated with the appropriate secondary antibody for 30 minutes, 
washed and subsequently incubated with avidin-horseradish peroxidase (HRP) complex 
(Invitrogen).  Slides were developed with chromogenic substrate for HRP (Zymed) and 
counterstained with hematoxylin.  Images were captured using a Zeiss Axio Imager M1 
microscope. 
CNS Infiltrate and Splenocyte Isolation:  CNS harvested after perfusion were homogenized 
using a syringe plunger.  Tissues were further homogenized by repeatedly passing through a 
syringe attached to an 18-gauge blunt needle.  CNS homogenates were fractionated on 30/70% 
Percoll gradient, and cells were recovered from the 30/70 interface.  For splenocyte isolation, 
spleens were homogenized between the frosted ends of two glass slides.  Homogenates were re-
suspended in ACK lysis buffer to lyse erythrocytes.  After washing, splenocytes were passed 
through a 70 µm cell strainer.  Cells were then prepared for flow cytometry analysis or cutured in 
vitro.   
Dextran Extravasation Assay:  At day 5 post EAE induction, 2 mg of texas red-labeled dextran 
(10,000 molecular weight) were i.v. injected into the systemic circulation of both IgG and anti-
PC treated mice.  5 hours after dextran injection, mice were perfused, and brains were harvested.  
Brains were homogenized in 50 mM Tris-HCl (1:1 per µl Tris-HCl to mg of brain weight).  
Homogenates were centrifuged and supernatants were collected.  Supernatants were mixed 1:1 
with methanol and centrifuged.  Fluorescence in supernatants was quantified using a BioTeck 
(Winnoski, VT) Synergy 4 plate reader.  Dextran concentration was based on a standard curve. 
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Flow Cytometry:  Cells were re-suspended in staining buffer (PBS with 0.5% BSA, and 0.09% 
sodium azide).  Cell suspensions were incubated with Fc block (BD Biosciences) for 10 minutes 
before incubation with primary antibodies for 30 minutes at 4
o
C.  Primary antibodies used are as 
follows: PE-conjugated anti-mouse CD4 (BD Biosciences), CD11b (eBioscience), CTLA-4 (BD 
Biosciences), FITC-conjugated anti-mouse CD8 (BD Biosciences), CD69, PerCP-conjugated 
anti-mouse CD25, NK1.1 (eBioscience), B220 (BD Biosciences), allophycocyanin-conjugated 
anti-mouse Ly6C, CD11c (eBioscience).  Foxp3 staining was done with the Ebioscience Foxp3 
staining kit in accordance with the manufacture’s protocol.  For iNOS intracellular staining, cells 
were fixed in 4% paraformaldehyde and permeabilized with .01% triton-x.  Cells were incubated 
with polyclonal rabbit anti-mouse iNOS (BD Biosciences) for 30 minutes.  Cells were washed 
and subsequently incubated with allophycocyanin-conjugated secondary antibody.  All samples 
were acquired using a FACSCanto II flow cytometer (BD Biosciences).  Raw data were 
evaluated using FlowJo Flow Cytometry Analysis Software (Treestar). 
Quantitative real-time PCR 
 Mice were perfused and CNS were harvested then homogenized.  Total RNA was 
extracted using Trizol (Invitrogen) according to the manufacturer’s protocol.  Extracted RNA 
was treated with Baseline-Zero DNAse (Epicentre) to remove contaminating genomic DNA.  1.5 
µg of total RNA was reverse transcribed using High-Capacity cDNA Reverse Transcription kit 
(Applied Biosystems CA, USA).  Real Time PCR was performed using SYBR Green technology 
(SYBR FAST Master Mix KAPAbiosystems) on a CFX96 Real Time System Thermal Cycler 
(Bio-RAD).  The cycling conditions were as follows:  Enzyme activation 95° C for 3 minutes 
followed by 40 cycles of denaturation 95°C for 3 secs, annealing 60° C for 30 seconds, 
elongation 72° C for 5 seconds.  BioRad CFX Manager software was used to determine cycle 
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threshold (Ct) values, and gene expression levels were calculated using the 2
-∆∆Ct
 method.  The 
expression levels of all genes of interest were normalized to the internal control gene, GAPDH.   
In vitro cell culture and ELISA:  Cells were cultured in complete RPMI (10% FBS, 
Penicillin/Streptomycin, L-glutamine, Sodium Pyruvate, 50mM 2-Mercaptoethanol, 25mM 
HEPES buffer).  Samples were cultured untreated or stimulated with MOG35-55 (10 µg/ml) for 48 
hours.  After culture, supernatants were collected for ELISA.  ELISA kits for IFN-γ and IL-10 
were from eBioscience, and assays were performed according to the manufacturer’s protocol. 
Proliferation Assay:  Splenocytes were labeled with CFSE (Molecular Probes, NY) according 
to the manufacturer’s protocol.  T-cells in whole-splenocyte culture were stimulated with plate-
bound anti-CD3 (1µg/ml) (Ebioscience) and soluble anti-CD28 (1µg/ml) (Biolegend) for 96 
hours.  After culture, splenocytes were labeled with PE-conjugated mouse anti-CD4 and acquired 
by flow cytometry to assess CFSE dilution.  For CD11b+/CD4+-cell co-culture, splenic CD11b+ 
cells were isolated using Easy Sep positive selection kit (Stem Cell Technologies), and splenic 
MOG-specific CD4+ T-cells from naive BL/6 2D2 transgenic mice were isolated using Easy Sep 
CD4+ selection kit (Stem Cell Technologies).  Cell isolation was done according the 
manufacturer’s protocol.  CD4+ T-cells were labeled with CFSE, stimulated with MOG35-55 (10 
µg/ml) and co-cultured with CD11b+ cells for 96 hours at a ratio of 1:4.  Proliferation was 
assessed by flow cytometry based on CFSE dilution.   
CD11b+ cells and CD4+ T-cells co-culture for T-reg expansion: CD11b+ and CD4+ cells 
were isolated as described above.  CD4+ T-cells were stimulated with anti-CD3/anti-CD28, as 
described above, and co-cultured with CD11b+ cells for 96 hours at a ratio of 1:2.  After culture, 
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CD4+ T-cells were stained with PerCP-conjugated anti-CD25 and allophycocyanin-conjugated 
anti-Foxp3.  Samples were acquired by flow cytometry to assess T-reg frequency. 
Arginase Activity:  Splenocytes were lysed with lysis buffer (0.1% triton-X, pepstatin 5µg, 
aprotinin 5µg, and antipain 5µg).  Arginase activity was measured as described previously [31].  
Sample absorbance was read with a Biotek EL x 50 plate reader at 550 nm.  
Nitrate/Nitrite Assay:  Splenocytes were cultured and supernatants were collected after 48 
hours.  Nitrate/Nitrite assay was done as described previously [32].  Absorbance was measured 
in a Biotek EL x 50 plate reader at 550 nm. 
 
Reactive Oxygen Species: Splenocytes were labeled with anti-Ly6C and anti-CD11b. Cells 
were washed and incubated with 10 uM of 2′,7′-Dichlorofluorescein diacetate (Sigma) for 30 
minutes at 37
o
C.  Cells were washed and incubated in 37
o
C for 30 mins.  Cells were acquired by 
flow cytometry to assess fluorescence corresponding with ROS generation.   
 
Immunofluorescence:  Splenocytes were cultured on coverslips in 24-well plates.  After culture, 
cells were washed and stained with FITC-conjugated anti-mouse CD11b (eBioscience) and 
allophycocyanin-conjugated anti-Ly6C (Ebioscience).  Cells were fixed with 4% PFA and 
permeabilized with 0.1% triton-X.  Cells were stained with polyclonal anti-arginase I (Genetex) 
and subsequently incubated with the appropriate secondary antibody.  After washing, coverslips 
were treated with Prolong Gold with Dapi (Molecular Probes) and mounted on slides.   Images 
were captured using a Zeiss Axio Imager M1 microscope. 
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Activated Protein C interaction with MDSC:  APC was labeled with FITC as previously 
described [30].  Splenic cells were labeled with anti-Ly6C and subsequently incubated with 
APC-FITC in HBSS buffer containing 0.5% BSA, 3mM CaCl2 and 0.6mM MgCl2 in the 
absence or presence of anti-PC antibody.  Cells were incubated on ice for 15 minutes, then 
acquired by flow cytometry to assess APC binding to Ly6C+ cells.   
 
Statistical Analyses:  Statistical analyses were performed using GraphPad Prism 5 software.  
Statistical significance was assessed by unpaired Student t test or by two-way 
ANOVA/Bonferroni post-test as indicated in figure legends. 
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 Results 
 
Inhibition of endogenous APC results in attenuated EAE. 
To determine whether APC can influence EAE pathogenesis, we inhibited endogenous 
APC in the circulation through administration of a monoclonal antibody to PC/APC (See 
Materials and Methods).  Anti-PC or IgG isotype at 10 mg/kg was administered at days 0, 2, 4, 
and 6 post EAE induction.  Administration of anti-PC within this timeframe inhibits APC during 
the initiation phase of the immune response, as well as at the outset of the effector phase of EAE, 
which is characterized by leukocyte infiltration into the CNS.  We observed that the onset of 
clinical symptoms in mice treated with anti-PC (anti-PC mice) was significantly delayed (Figure 
2.1 and Table 2.1).   The mean day of onset for anti-PC mice was 16.7 days post EAE induction 
while controls exhibited clinical symptoms as early as day 7 with mean onset at 10.5 days post 
immunization.  Additionally, incidence of disease was higher in the control group; 80% of 
controls developed EAE by day 16 and 100% exhibited symptoms by day 22 (Table 2.1).  In 
contrast, only 44% of anti-PC mice exhibited clinical symptoms on day 16 and 66% by day 22.  
These data show that inhibition of endogenous APC can alter the disease course of EAE, albeit 
in a rather unexpected way, given that inhibition of APC, an anti-inflammatory molecule, 
resulted in attenuation of EAE rather than increasing disease severity.       
 
 
  
43 
 
 
 
Figure 2.1 Mice treated with anti-PC antibody exhibit attenuated EAE.  To induce EAE, 
BL/6 mice were immunized with MOG35-55 in CFA; pertussis toxin was i.v. injected on the day 
of immunization, and a second dose was injected 48 hours later.  Anti-PC or IgG control was i.p. 
injected on days 0, 2, 4, and 6 post EAE induction.  Mice were monitored daily to assess clinical 
symptoms, and scores were assigned based on the scoring system outlined in materials and 
methods.  Scores were plotted as the mean + S.E.M (anti-PC n = 9, IgG control n = 10.  On day 
16, mice from both groups were randomly selected for tissue collection.  
* p < 0.01, *** p < 0.001 by two-way ANOVA/Bonferroni post-test;  Statistical analysis up to 
day 16 included all mice. Statistical analysis up to day 22 did not include mice taken for tissue 
collection on day 16).  The result shown is representative of four independent experiments.       
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Table 2.I Anti-PC mice exhibit attenuated EAE 
     IgG Control     Anti-PC 
Mean Day of Onset 
a 
 
     10.5 (+ 3.4) 16.7 (+ 3.3)* 
Mean Maximum Clinical 
Score
b
 by Day 16
 
 
        2.2         0.94 
Incidence by Day 16 
 
        80%          44% 
Mean Maximum Clinical 
Score
b
 by Day 22
# 
 
        3.0          1.6 
Incidence by Day 22
#        100%          66% 
   
 
 
a 
Day of Onset denotes the first day each mouse exhibited clinical symptoms after EAE 
induction.  For mice that were not showing clinical symptoms at the time of tissue collection, the 
day following tissue collection was assigned as the day of onset.  + S.E.M are indicated inside 
the parenthesis; * p < 0.05.   
b
Maximum clinical score denotes the highest score each mouse reached during the course of 
EAE progression.  
#
Day 22 calculation for mean maximum clinical score and incidence does not include the mice 
that were taken for tissue collection on day 16.  
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Anti-PC mice have considerable leukocyte infiltration in the brain despite exhibiting attenuated 
clinical symptoms. 
The major pathological component in EAE is leukocyte infiltration into the CNS, which 
typically correlates with the severity of clinical signs [24, 25].  To investigate why anti-PC mice 
had attenuated disease, we assessed the severity of CNS infiltration at the peak of disease (days 
14-17).  We observed that the extent of leukocyte (CD45
+
 cells) infiltration in the brains of 
control mice positively correlates with disease severity (Figure 2.2A-C).  Interestingly, 33% 
(Appendix-A Table I) of anti-PC mice with no clinical symptoms had considerable CD45+ 
infiltrates in the brain, comparable to controls with severe EAE (Figure 2.2A-C).  We noted that 
cellular infiltrates were located in similar areas of the brain in both groups, notably in the 
hippocampal area (Figure 2.2 A), the cerebellar parenchyma (Figure 2.2B), and at the meninges 
(Figure 2.2C).  We additionally observed that the extent of infiltration in the spinal cords (SC) of 
controls corresponds with the severity of symptoms (Figure 2.2D).  Interestingly, the degree of 
cellular infiltration in the SC of anti-PC mice was minimal despite considerable infiltration in the 
brain (Figure 2.2D).  Perivascular cuffing, characterized by cellular infiltrates encircling blood 
vessels in the CNS, is a hallmark of EAE pathology and is indicative of increased BBB 
permeability [33].  We observed rampant perivascular cuffing in the brain parenchyma of anti-
PC mice (Figure 2.2E), suggesting increased BBB permeability in these mice.  To confirm 
whether inhibition of APC resulted in increased BBB permeability, fluorescent dextran 
molecules were injected into the systemic circulation of both control and anti-PC mice, and we 
assessed the degree of dextran extravasation into the brain.  We consistently observed increased 
dextran extravasation in the brains of anti-PC mice compared to controls (Fig 2.2F), further 
exhibiting increased BBB permeability in anti-PC mice.  Overall, these data demonstrate that 
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despite exhibiting attenuated clinical symptoms, inhibition of APC during EAE resulted in 
increased BBB permeability as evidenced by pronounced leukocyte infiltration and increased 
dextran extravasation in the brains of anti-PC mice. 
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Figure 2.2  Anti-PC mice show considerable infiltration in the brain despite exhibiting 
attenuated clinical symptoms.  CNS were harvested at the peak of disease (days 14-17) 
following EAE induction.  CNS sections were stained with anti-CD45 (red) and various areas of 
the CNS, specifically (A) the hippocampal area, (B) cerebellar parenchyma, (C) brain meninges, 
and (D) spinal cord were assessed for the presence of cellular infiltrates.  Arrows indicate areas 
of the CNS with pronounced CD45
+
 staining.  (E) Histological representation showing CD45
+
 
cellular infiltrates surrounding blood vessels in the brain parenchyma of anti-PC mice.  (F) At 
day 5 post EAE induction, fluorescent dextran molecules (2 mg) were i.v. injected into the 
systemic circulation of anti-pc and control mice.  Brains were harvested 5 hours later to assess 
the degree of dextran extravasation.  The concentration of extravasated dextran in brain 
homogenates was determined based on a standard curve. 
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Anti-PC mice exhibit reduced CD4
+
 pathogenic subsets in the brain while the CD4
+
 T-
regulatory subset is increased. 
To further investigate the disparity in disease course between anti-PC and control mice, 
we next examined the frequency of specific leukocyte infiltrates in the CNS.  We did not observe 
significant differences in CD4
+
 T-cell frequency in the brains (Figure 2.3A) and in the SC 
(Figure 2.3C) between the two groups.  Various CD4
+
 T-cell subsets have differing effects on 
EAE severity; notably, the T-regulatory (T-regs) subset (CD4
+
CD25
+
Foxp3
+
) confers protection 
in EAE, while T-helper 1 (TH1) and T-helper 17 (TH17) subsets are pathogenic [25].  We 
observed significantly increased T-reg frequency in the brains of anti-PC mice compared to 
controls (Figure 2.3B).  T-reg frequency is similarly increased in the SC of anti-PC group, 
although the difference did not reach statistical significance (Figure 2.3C).  The protective effect 
of T-regs is partly mediated through the production of the anti-inflammatory cytokine, IL-10  
[34].  Consistent with increased T-reg frequency, we detected increased IL-10 production from 
cellular infiltrates in the brains and SC of anti-PC mice (Figure 2.3D).  In contrast, the 
production of the TH1 cytokine, IFN-γ, is reduced in brain infiltrates (but not from SC infiltrates) 
from anti-PC mice (Figure 2.3D).  We similarly detected decreased IL-17 mRNA expression in 
the brains and SC of anti-PC compared to controls (Figure 2.3 E), suggesting that the presence of 
the pathogenic TH17 subset in the CNS of anti-PC mice is reduced.  Collectively, these data 
show that despite considerable infiltration in the brains of anti-PC mice, the pathogenic CD4
+
 
subsets and their respective signature cytokines required for disease progression are reduced in 
the brains of anti-PC mice while the suppressive T-reg population is increased.  We additionally 
examined the frequency of non-CD4 leukocytes in the brain but found no significant differences 
(Appendix-B).   
50 
 
 
  
 
1.72 %
2.24 %
IgG ControlC
D
4
CD3
Anti-PC
IgG Control Anti-PC
0.0
0.5
1.0
1.5
%
 C
D
4 
T-
Ce
lls
A.
51.1 %
Anti-PC
33.0 %
IgG Control
F
O
X
P
3
CD25
B.
IgG Control Anti-PC
0
20
40
60
%
  T
-r
eg
s 
**
IgG Control Anti-PC
0
1
2
3
4
C.
%
 C
D
4 
T-
Ce
lls
IgG Control Anti-PC
0
10
20
30
%
 T
-r
eg
s
D.
B
ra
in
 IL
-1
0 
pg
/m
l
IgG Control Anti-PC
0
200
400
600
800
1000
IgG Control Anti-PC
0
50
100
150
SC
  I
L-
10
 p
g/
m
l
IgG Control Anti-PC
0
100
200
300
400
500
B
ra
in
 IF
N
-γ
pg
/m
l
IgG Control Anti-PC 
0
200
400
600
SC
 IF
N
-γ
p
g/
m
l
E.
IgG Control Anti-PC 
0
2
4
6
8
B
ra
in
 I
L
-1
7
A
 E
x
p
re
s
s
io
n
 F
o
ld
 C
h
a
n
g
e
IgG Control Anti-PC
0
20
40
60
80
S
C
 I
L
-1
7
A
 E
x
p
re
s
s
io
n
F
o
ld
 C
h
a
n
g
e
51 
 
Figure 2.3 Anti-PC mice show increased T-regulatory cells and IL-10 production in the 
CNS.  (A) At day 17 following EAE induction, cellular infiltrates from brains of anti-PC and 
control mice were isolated by percoll gradient, and cells were subjected to flow cytometry 
analysis to assess the frequency of CD4
+
 T-cells.  Flow cytometric dot plot is shown on the upper 
panel, and data are represented as means + SEM at the bottom panel (Control n = 6, anti-PC n = 
4).  (B) The frequency of T-regs (CD25+, Foxp3+) among CD4
+
 T-cell infiltrates in the brain 
was assessed by flow cytometry.  Data are shown as flow cytometric contour plot (gated on 
CD3
+
CD4
+
 cells) on the upper panel and as means + SEM on the bottom panel.  (Control n = 6, 
anti-PC n = 4, ** p < 0.01 by Student t test)  (C) Leukocyte infiltrates from the spinal cords of 
anti-PC mice and controls were isolated by percoll gradient and assessed for the frequency of 
CD4
+
 T-cells (upper  panel) and T-regs among CD4
+
 T-cells (bottom panel) at day 16 following 
EAE induction.  Data are represented as means + SEM (n = 5-6).  (D) CNS infiltrates from both 
anti-PC and control mice were isolated as described above.  Cells from individual mouse (n < 3) 
were pooled for each group and re-stimulated with MOG35-55 in vitro.  After 48 hours, 
supernatants were collected and the production of IL-10 (upper panel) and IFN-γ (bottom panel) 
were measured by ELISA.  Cytokine concentrations were determined based on standard curves. 
(E) Brains and SC were homogenized, and whole-cell mRNA was isolated using the Trizol-
based extraction process.  IL-17A mRNA was quantified using real-time quantitative PCR, and 
expression levels were calculated using the 2
-∆∆Ct
 method.  The expression levels of IL-17A were 
normalized to the internal control gene, GAPDH.  IL-17A expression is represented as fold 
change in expression relative to naïve mice (non-EAE induced).      
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Anti-PC mice exhibit reduced microglial activation and minimal demyelination in the CNS. 
 We next examined the extent of CNS pathology in control and anti-PC mice.  Activated 
microglial cells greatly contribute to CNS pathology in EAE, including demyelination, axonal 
pathology and neurodegeneration, leading to the clinical signs of the disease [35, 36].  To assess 
the degree of microglial activation, CNS sections were stained for the microglial marker Iba-1, 
which is upregulated on activated microglial cells [35, 36].  Control mice with severe EAE 
showed markedly pronounced staining for Iba-1 (Figure 2.4A), suggesting increased microglial 
activation in the brains of these mice.  In contrast, Iba-1 staining in the brains of anti-PC mice 
was less prominent (Figure 2.4A), indicative of reduced microglial activation in these mice.  The 
hallmark pathology in EAE is demyelination.  We assessed the extent of demyelination in the 
CNS of both groups.  We detected extensive demyelination in the brains and SC of control mice 
(Figure 2.4B), corresponding to the severity of clinical signs and the degree of leukocyte 
infiltrates in the CNS.  Conversely, the CNS of anti-PC mice exhibit minimal demyelination 
(Figure 2.4B).  Taken together, these data further demonstrate the decreased inflammatory and 
pathogenic conditions in the CNS of anti-PC mice despite the presence of cellular infiltrates. 
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Figure 2.4 Anti-PC mice exhibit minimal microglial activation and demyelination in the 
CNS.   CNS were harvested at the peak of disease (days 14-17) following EAE induction.  (A) 
Brain sections from control and anti-PC mice were stained with anti-Iba-1 (red) to assess 
microglial activation.  Arrows indicate pronounced Iba-1 staining.  (B) CNS sections were 
examined for severity of demyelination by staining with anti-MOG antibody.  Areas in the CNS 
that do not positively stain for MOG denote demyelination as indicated by arrows.     
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Peripheral CD4
+
 T-cells in anti-PC mice are significantly decreased and functionally deficient. 
 In EAE, leukocyte infiltration in the CNS is preceded by initial activation of immune 
populations in the periphery [37].  Since APC can directly modulate various leukocyte functions 
[9, 13], we hypothesize that abrogating APC activity in the circulation at the initiation of EAE 
can likely affect the activation and functional responses of peripheral leukocytes.  We, therefore, 
examined the frequency and functional characteristics of various leukocyte populations in the 
periphery.  We observed significantly decreased splenic CD4
+
 T-cells in anti-PC mice compared 
to controls (Figure 2.5A).  Moreover, consistent with what we observed in the CNS, the 
frequency of T-regs is significantly increased in the periphery of anti-PC mice (Figure 2.5B).  
We evaluated the expression levels of various cell surface markers on splenic T-cells.  
Interestingly, we observed that the ratio of CD3
high 
to CD3
low
 T-cells is consistently reduced in 
anti-PC mice compared to controls (Figure 2.5C).  Reduced CD3 expression has been attributed 
to lowered T-cell activation [38].  The expression levels of other CD4
+
 T-cell surface markers, 
however, were not altered (Appendix-C).  We next assessed the proliferative capacity of splenic 
CD4
+
 T-cells from both experimental groups.  CD4
+
 T-cells in whole-splenocyte culture were re-
stimulated in vitro, and we observed that CD4
+
 T-cell from control mice exhibited robust 
proliferation, while the proliferative capacity of CD4
+
 T-cells from anti-PC mice is significantly 
diminished (Figure 2.5D).   Taken together, these data are indicative of a decreased and deficient 
CD4
+
 T-cell effector function in anti-PC mice.  Furthermore, the suppressive T-reg population is 
significantly increased in the periphery of anti-PC mice.  
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Figure 2.5  Peripheral CD4+ T-cells in anti-PC mice are significantly decreased and 
functionally deficient.  (A)  The frequency of splenic CD4
+
 T-cells from anti-PC and control 
mice was examined by flow cytometry at day 17 following EAE induction.  Data are represented 
as flow cytometric dot plots on the left panel.  Middle panel and right panel are the graphical 
representation of the mean percentage of splenic CD4
+
 T-cells and the mean absolute cell counts 
of splenic CD4
+
 T-cells, respectively.  Data are represented as means + SEM (control n = 6; anti-
PC n = 4; * p < 0.05 by Student t test).   (B) The frequency of splenic T-regs (CD4
+
, CD25
+
, 
Foxp3
+
) among CD4
+
 T-cells was assessed by flow cytometry.  Left panel shows the graphical 
representation of the mean percentage of T-regs among CD4
+
 T-cells.  Data are shown as means 
+ SEM (control n = 6; anti-PC n = 4; * p < 0.05 by Student t test).  Middle and right panels show 
data as flow cytometric contour plots (gated on CD3
+
CD4
+
).   (C) Flow cytometric dot plot 
representing the percentage of CD3
high 
and CD3
low
 splenic cells from both experimental groups 
(gated on CD3
+
 cells).  (D)  Splenocytes from control and anti-PC mice were labeled with CFSE 
and cultured in vitro.  T-cells in whole splenocyte culture were stimulated with plate-bound anti-
CD3 and soluble anti-CD28 for 96 hours.  The proliferative capacity of CD4
+ 
T-cells was 
assessed by flow cytometry based on CFSE dilution.  Left panels show the histogram 
representation of CFSE labeled CD4
+
 T-cells from both experimental groups (gated on CD4
+
 
cells).  Data on right panel are the graphical representation of the mean percentage of CD4
+
 T-
cells that have proliferated based on CFSE dilution.  Data represented as means + SEM (n=4; ** 
p < 0.01 by Student t test). 
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CD11b
+
 cells are significantly increased in the periphery of anti-PC mice. 
 We next examined the frequencies of other splenic populations from both control and 
anti-PC mice.  Similar to CD4
+
 T-cells, the frequency of CD8
+
 T-cells is significantly decreased 
in anti-PC mice (Figure 2.6A).  Moreover, while we did not observe significant changes in the 
frequencies of various non-T-cell populations between the two experimental groups (Figure 
2.6A), we did, however, observe increased splenic CD11b
+
 cells in anti-PC mice compared to 
controls, and this was consistent through different time points in EAE (Figure 2.6B).  Since 
various leukocyte subsets are known to express CD11b, we next determined the frequency of 
specific CD11b-expressing leukocyte subsets.  We observed significantly increased macrophages 
(CD11b
+
F480
+
) and dendritic cells (DC) (CD11b
+
CD11c
+
) in anti-PC mice (Figure 2.6C).  A 
population of blood monocytes known as myeloid-derived suppressor cells (MDSC), and 
characterized to be potent T-cell suppressors, has also been shown to express CD11b [39].  
Various studies have used the co-expression of CD11b and Ly6C as identifying markers for 
MDSC in mice [29, 40].  Consistent with other CD11b
+
 populations, we observed increased 
frequency of MDSCs in anti-PC mice, and this was observed through various stages in EAE 
(Figure 2.6D). 
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Figure 2.6.  CD11b
+
 cells in the periphery of anti-PC mice are significantly increased.   
(A-D) Splenocytes were harvested from the anti-PC and IgG control mice at day 17 following 
EAE induction, and the frequency of several leukocyte populations was assessed by flow 
cytometry.  (B) Left panel shows the flow cytometric dot plot representing the splenic CD11b 
frequency of both experimental groups.  The right panel shows the frequency of CD11b
+
 cells in 
the spleen at various stages of EAE progression as assessed by flow cytometry.  (C)  Splenocyte 
frequency of specific Cd11b expressing populations, namely macrophages (CD11b
+
 F480
+
) 
(upper panel) and DC’s (CD11b
+
 CD11c
+
) (bottom panel), was examined by flow cytometry.  
(D) The frequency of MDSCs was examined in the spleen by staining for cell surface markers, 
CD11b and Ly6C.  Frequencies were analyzed by flow cytometry.  Left panel represents flow 
cytometric dot plot of CD11b
+
LyC
+
 cells from both anti-PC and control mice.  Right panel 
exhibits the percentage of MDSC’s populations in the spleen from both experimental groups at 
various stages of EAE progression.   Data are represented as means + SEM (n = 3-6; * p < 0.05; 
** p < 0.01; *** p < 0.001 by Student t test).        
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CD11b
+
 cells from anti-PC mice suppress the proliferation of CD4
+
 T-cells and increase the 
proliferation of T-regulatory cells 
  
 We have observed that the frequency and effector functions of CD4
+
 T-cells in anti-PC 
mice are significantly diminished (Figure 2.5).  Studies have shown that certain populations of 
CD11b
+
 cells, specifically MDSCs [29], are effective regulators of T-cell function.  We, 
therefore, hypothesize that the deficit in CD4
+
 T-cell numbers and diminished CD4
+
 effector 
functions observed in anti-PC mice is a consequence of increased expansion of suppressive 
CD11b
+
 cells.  We tested this hypothesis by isolating CD11b
+
 cells from both groups and 
examined their ability to suppress the proliferation of MOG35-55-specific CD4
+
 T-cells.  We 
observed that CD11b
+
 cells from anti-PC mice were more effective in suppressing MOG35-55-
induced proliferation of CD4
+
 T-cells compared to CD11b
+
 cells from controls (Figure 2.7A).  
No difference in proliferation, however, was observed if CD4
+
 T-cells were co-cultured with 
non-CD11b
+
 cells from either anti-PC or control mice (Figure 2.7B).  Moreover, we have 
previously observed that the cell-surface expression of CD3 is reduced on splenic T-cells in anti-
PC mice (Figure 2.5C).  Consistently, we observed that CD4
+
 T-cells co-cultured with CD11b
+
 
cells from anti-PC exhibit significantly lowered CD3 expression compared to CD4
+
 T-cells co-
cultured with CD11b
+
 cells from control mice (Figure 2.7C).  A number of studies have shown 
that MDSCs can directly mediate T-reg expansion [29, 40, 41].  We, therefore, hypothesize, that 
the increased frequency of T-regs, which was observed both in the CNS (Figure 2.2B) and 
periphery (Figure 2.5B) of anti-PC mice, is similarly mediated by the increased CD11b
+
 
suppressor cells in these mice.  We tested this hypothesis by co-culturing in vitro- stimulated 
CD4
+
 T-cells with CD11b
+
 cells from either anti-PC or control mice.  We observed significantly 
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higher frequency of T-regs following co-culture with CD11b
+
 cells from anti-PC mice (Figure 
2.7E).  Altogether, these data exhibit the increased suppressive capability of CD11b
+
 cells in 
anti-PC mice, mediated through direct suppression of T-cell function and the induced expansion 
of T-regs.  
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Figure 2.7.  CD11b
+
 cells from anti-PC mice suppress CD4
+
 T-cell proliferation and 
increase CD4+ T-regulatory cells.  (A)  Following EAE induction, splenic CD11b
+
 isolated 
from anti-PC or control mice were co-cultured for 96 hours with MOG35-55-specific CD4
+
 T-cells 
isolated from BL/6 2D2 mice.  To assess proliferation, CD4
+
 T-cells were labeled with CFSE 
and stimulated with MOG35-55.  CFSE dilution was assessed by flow cytometry.  Left panel 
represents flow cytometric dot plot of CFSE labeled CD4
+
 T-cells co-cultured with CD11b
+
 cells 
from either anti-PC or control mice.  Right panel shows percentage of CD4
+ 
T-cells that have 
proliferated based on CFSE dilution.  Data are represented as means + SEM (n = 3; p calculated 
by Student t test).  (B) Non-CD11b
+
 splenocytes from anti-PC or control mice were co-cultured 
for 96 hours with CD4
+
 T-cells from BL/6 2D2 mice.  CD4
+
 T-cells were labeled with CFSE and 
stimulated with MOG35-55 for 96 hrs.  Proliferation of CD4
+
 T-cells was analyzed by flow 
cytometry based on CFSE dilution.  Left panel represents flow cytometric dot plot of CFSE 
labeled CD4
+
 T-cells co-cultured with non-CD11b
+
 cells from anti-PC or control mice.  Right 
panel shows percentage of CD4
+
 T-cells that have proliferated based on CFSE dilution.   Data 
are represented as means + SEM (n = 3).  (C)  The expression of cell-surface CD3 on CD4
+
 T-
cells that were co-cultured with CD11b
+
 cells from either anti-PC or control mice was assessed 
by flow cytometry, and the difference in CD3 expression levels was determined by mean 
fluorescence intensity (MFI).  Data shown as mean MFI + SEM (n=4; * p < 0.05 by Student t 
test).  (D) CD11b
+
 cells were isolated from anti-PC or IgG control mice following EAE 
induction, and co-cultured for 96 hours with CD4
+
 T-cells that were stimulated with plate-bound 
anti-CD3 and soluble anti-CD28.  After co-culture, the frequency of T-regs among CD4
+
 T-cells 
was assessed by flow cytometry.  Left panel is the histogram representation of foxp3 expression 
in CD4
+
CD25
+
 cells from the two co-culture conditions.  Right panel shows the mean percentage 
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of foxp3+ cells among CD4
+
 CD25
+
 T-cells.  Data are represented as means + SEM (n = 3; * p < 
0.05 by Student t test).   
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Arginase I activity, iNOS expression, and reactive oxygen species production are increased in 
CD11b
+
 cells from anti-PC mice 
 Several studies have demonstrated that the suppressive capacity of MDSC on T-cells is 
largely mediated through one or a combination of arginase I (Arg I) activity, nitric oxide (NO) 
production, and generation of reactive oxygen species [29, 39].  Arg I activity converts L-
Arginine (L-Arg), into urea and L-ornithine [39].  Increased Arg I activity in MDSCs depletes L-
Arg from the microenvironment, resulting in suppression of various T-cell responses, including 
inhibition of T-cell proliferation, reduced CD3ζ chain expression, and in some studies increased 
Arg I activity has been implicated in MDSC-mediated T-reg expansion [38, 39, 42].  Consistent 
with the increase of MDSCs, we measured higher arginase activity in splenocytes from anti-PC 
mice (Figure 2.7A), and we additionally show by immunofluorescence that Arg I is specifically 
expressed by CD11b
+
 and CD11b
+
 Ly6C
+
 cells (Figure 2.7B).  MDSCs are also known to 
express elevated levels of iNOS, which utilizes L-Arg as a substrate to produce nitric oxide 
(NO), contributing to L-Arg depletion [29, 39].  Moreover, NO production is known to directly 
inhibit T-cell functions, including the induction of T-cell apoptosis [29, 39].  We observed 
significantly increased iNOS expression in CD11b
+
 and CD11b
+
Ly6C
+
 populations from anti-PC 
mice (Figure 2.7C), coupled with elevated NO production (Figure 2.7D).  Another mechanism 
for MDSC-mediated T-cell suppression has been attributed to the generation of ROS, which can 
inhibit antigen-specific T-cell proliferation and downregulate CD3ζ chain expression [29, 39].  
We observed significantly higher generation of ROS in CD11b
+
 cells (Figure 2.7E) and Ly6C
+
 
cells (Figure 2.7F) from anti-PC compared to controls.  Collectively, these data demonstrate that 
CD11b
+
 cells from anti-PC mice express and generate elevated levels of specific factors that 
have been implicated in the suppression of T-cell functions. 
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Figure 2.8  Arginase I activity, iNOS expression, and reactive oxygen species production 
are increased in CD11b
+
 cells from anti-PC mice.  (A) Splenocytes were collected following 
EAE induction, and arginase activity in splenocytes was measured based on urea generation.  
Data are represented as means + SEM (n = 4).  (B)  Splenocytes were cultured on cover slips 
overnight, and cells were stained with fluorochrome-conjugated antibodies to CD11b, Ly6C, and 
arginase.  Coverslips were mounted on slides, and images were captured using a Zeiss Axio 
Imager M1 microscope.  (C)  The expression of iNOS in CD11b
+
 and CD11b
+
 Ly6C
+
 cells was 
assessed by flow cytometry.  Left and middle panel show the flow cytometric histogram of iNOS 
expression in CD11b
+
 and CD11b
+
 Ly6C
+
 cells, respectively.  Right panel represents the mean 
fluorescence intensity (MFI) of iNOS expression in CD11b
+
 and CD11b
+
Ly6C
+
 cells.  Data are 
represented as means + SEM (n = 3; ** p < 0.01 by Student t test).  (D)  Splenocytes were 
cultured for 48 hours, and supernatants were collected to assess NO production using Griess 
assay.  Data are represented as means + SEM (n = 3).  (E – F)  ROS generation is assessed by 
incubating splenocytes with  2’,7’ –dichlorofluorescein diacetate, a compound which diffuses 
into cells and fluoresces upon oxidation by ROS.  Degree of cell fluorescence, which increases 
with elevated ROS generation, was assessed by flow cytomerty.  (E)  Left panel shows the flow 
cytometric dot plot of ROS
+
 CD11b
+
 cells from both experimental groups.  Right upper panel is 
the histogram representation of the degree of ROS production in CD11b
+
 cells, and bottom right 
panel shows the average MFI correlating to ROS generation in CD11b
+
 cells.   Data are 
represented as means + SEM (n = 4; * p < 0.05).  (F) Left panel shows the flow cytometric dot 
plot of ROS
+
 Ly6C
+
 cells.  Right upper panel is the histogram representation of the level of ROS 
production in Ly6C
+
 cells, and bottom right panel shows the average MFI of ROS generation in 
Ly6C
+
 cells.   Data are represented as means + SEM (n = 4; * p < 0.05). 
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Signal transducer and activator of transcription 3 (Stat3) is significantly increased in CD11b+ 
cells from anti-PC mice 
 
 The transcription factor, Stat3, has been shown to have a critical role in the expansion 
and suppressive capacity of MDSCs [29, 39].  Several studies have demonstrated that inhibition 
of Stat3 abrogated the expansion and suppressive activities of MDSCs [43, 44].  We therefore 
specifically examined the expression of Stat3 in CD11b
+
Ly6C
+
 cells from both anti-PC and 
control mice.  We observed significantly increased Stat3 expression in splenic CD11b
+
Ly6C
+
 
cells from anti-PC mice (Figure 2.9A).  We additionally observed increased phosphorylated 
Stat3 (pStat3) in Ly6C
+
 cells from anti-PC mice (Figure 2.9B), suggesting elevated Stat3 
activation in these cells.  These data further confirm that the CD11b
+
Ly6C
+
 population in anti-
PC mice demonstrate the suppressive MDSC phenotype.  
  
  
 
 
  
 
 
 
Figure 2.9
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APC directly interacts with MDSCs 
 APC has traditionally been known to regulate various cell types, including leukocytes, 
through its direct interaction with the cellular receptor, EPCR, subsequently enabling APC to 
activate PAR-1 [3].  A number of studies, however, have demonstrated that APC can regulate 
leukocyte functions through its interactions with receptors other than EPCR [45, 46].  One 
particular study has shown that APC can directly regulate the inflammatory responses of myeloid 
cells by binding to the CD11b integrin expressed on the cell surface [15].  In this study, Cao et. 
al demonstrated that APC can bind CD11b on macrophages, subsequently enabling APC to 
activate PAR-1 and resulting in the inhibition of pro-inflammatory responses, including 
downregulation of iNOS and Stat3 [15].  Based on this particular study, which demonstrates that 
APC is a potent negative regulator of CD11b
+
 cells though direct interaction with the CD11b 
integrin, we hypothesize that inhibition of APC during EAE resulted in the increased expansion 
and activation of various CD11b
+
 populations, as was observed in anti-PC mice.  Moreover, we 
propose that among the CD11b
+
 populations that increased and become more activated as a 
result of APC inhibition is the suppressive MDSC population, which ultimately contributed to 
attenuating EAE.  We confirmed that MDSCs express PAR-1 (Figure 2.10A), suggesting that 
these cells express the necessary receptor to be responsive to APC regulation.  We next 
determined whether APC can directly interact with MDSCs.  Fluorochrome-conjugated APC’s 
were incubated with Ly6C
+
 cells, and we show by flow cytometry that APC directly binds 
Ly6C
+
 cells (Figure 2.10B).  Moreover, we confirm that the monoclonal antibody to PC used to 
inhibit APC in EAE mice can abrogate the direct binding of APC to Ly6C
+
 cells (Figure 2.10C).  
Collectively these data demonstrate that APC directly interacts with Ly6C
+
 cells, indicative of 
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Figure 2.10 APC directly interacts with Ly6C
+
 cells.  (A)  Splenic cells were stained with anti-
PAR-1 to determine the expression of PAR-1 on Ly6C
+
 cells.  Left panel shows the histogram 
representation of PAR-1 expression on Ly6C
+
 cells stained with either isotype control or anti-
PAR-1.  Right panel shows the graphical representation of MFI corresponding to PAR-1 
expression on Ly6C
+
 cells.  (B) To determine whether APC can directly interact with Ly6C
+
 
cells, fluorochrome-conjugated APC were incubated with splenic cells, and the binding of APC 
to Ly6C
+ 
cells was assessed by flow cytometry.  (C)  To examine whether anti-PC can decrease 
the interaction of APC to Ly6C
+
 cells, fluorochrome-conjugated APC were incubated with 
splenic cells with or without anti-PC, and the binding of APC to Ly6C
+
 cells was assessed by 
flow cytometry.  Left panel exhibits the histogram representation of the extent of APC binding to 
Ly6C
+
 cells, and right panel is the graphical representation of MFI corresponding to APC 
binding to Ly6C
+
 cells. 
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Discussion 
 
In addition to its traditional function as an anti-coagulant, APC can influence various 
aspects of the pathological setting by directing cellular processes involved in inflammatory 
responses, vascular integrity, and cell survival [1-3].  Our study further exemplifies the broad-
ranging effects of APC in pathological conditions.  We observed that depletion of APC during 
EAE affected disease pathogenesis at multiple fronts.  What is interesting and unexpected, 
however, is that the various effects of APC-depletion on the inflammatory response in EAE have 
opposing and incongruent consequences on the progression and severity of the disease.  We 
observed that inhibition of APC increased BBB permeability as evidenced by considerable 
leukocyte infiltration and increased dextran extravasation in the brains of anti-PC mice.  
However, APC depletion also had considerable effects on the inflammatory responses of various 
leukocyte populations.  Inhibition of APC effectively resulted in increased and more activated 
CD11b
+
 myeloid population, including the expansion of the MDSC subset that is capable of 
negatively regulating the effector T-cells required for disease progression.  Consequently, the net 
effect of APC inhibition in EAE is attenuated disease.   
The ability of APC to influence inflammatory conditions has been largely attributed to its 
cell signaling capabilities [1-3].  APC can regulate the functions of various cell types including 
several leukocyte populations.  The cellular receptors that are involved in APC- mediated 
signaling in leukocytes, however, is still unclear.  In endothelial cells, APC controls cellular 
processes by interacting with EPCR, a receptor which localizes APC on the cell surface and 
within the lipid rafts of the cell membrane, allowing APC to activate PAR-1 and initiate various 
cell signaling cascades [5, 7].  Several studies, however, have shown that APC’s effects on 
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myeloid cells are not dependent on EPCR and may involve other cellular receptors [46, 47].  A 
recent study by Cao et. al. has identified the CD11b integrin as the facilitator of APC’s anti-
inflammatory effects on macrophages [15].  In this study, the group demonstrated that APC can 
effectively inhibit the pro-inflammatory responses in macrophages, including down-regulation of 
iNOS, STAT3, and NF-κB expression, through APC’s interaction with CD11b on the cell 
surface [15].  They propose that CD11b expressed on leukocytes can serve a similar function as 
EPCR on endothelial cells, in that CD11b can bind APC and co-localize it with PAR-1 within 
the lipid rafts of the cell membrane, thereby facilitating PAR-1 activation, and inhibiting 
inflammatory signaling cascades [15].   
In accordance with the study by Cao et. al, we observed that inhibition of APC during 
EAE resulted in the significant increase in various CD11b
+
 populations.  Since APC has been 
shown to be a negative regulator of CD11b
+
 cells, we hypothesize that inhibition of APC during 
EAE likely resulted in the increased and more activated CD11b
+
 subsets.  Further, we propose 
that certain CD11b
+
 populations, notably MDSCs, which similarly expanded as a result of APC 
inhibition, can have suppressive effects on the progression of EAE, thus resulting in the 
attenuated disease observed in anti-PC mice.   
MDSCs are a heterogenous population of immature myeloid cells characterized to be 
potent T-cell suppressors [29, 39, 40].  In mice, MDSCs are identified by cell surface co-
expression of CD11b and Gr-1 [29].  Antibodies to Gr-1 bind two epitopes, Ly6C and Ly6G. 
MDSCs are categorized into two subsets based on the cell surface expression of these two 
molecules [29, 39, 40].  The CD11b
+
Ly6C
hi
Ly6G
+
 subset has a monocytic morphology while the 
CD11b
+
Ly6C
low
Ly6G
-
 subset was described to have a granulocytic morphology [29, 39, 40].  
Each subset employs distinct mechanisms for suppressing T-cell function.   Since both MDSC 
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subsets express Ly6C, we utilized the co-expression of CD11b and Ly6C as identifying markers 
for the MDSC population; thus, the MDSC population identified in our study incorporates both 
MDSC subsets.  The immunoregulatory effects of MDSCs on T-cells has initially been described 
in tumor micro-environments, but recent studies have also reported the suppressive capabilities 
of MDSCs in various pathological settings, including parasitic infections and autoimmunity [40].  
The suppressive capacities of these cells have been specifically observed in EAE.  
CD11b
+
LyC
high
 cells were shown to increase in the spleen following EAE induction, and these 
cells are capable of suppressing the proliferation of CD4
+
 and CD8
+
 T-cells [48].  In another 
study, MDSCs were observed in the spinal cord (SC) during EAE where they can promote T-cell 
apoptosis, thus limiting inflammation [49].  In agreement with these studies, we observed that 
anti-PC mice with attenuated EAE have increased splenic CD11b
+
Ly6C
+
 cells.  Moreover, we 
observed that the frequency and the proliferative capacity of CD4
+
 T-cells are significantly 
reduced in these mice, consistent with the known suppressive effects of MDSCs on T-cell 
proliferation.  We also observed that the proliferation of MOG35-55-specific T-cells is inhibited 
when co-cultured with CD11b
+
 cells isolated from anti-PC mice, confirming the direct 
suppressive capability of the CD11b
+
 population from the anti-PC mice on antigen-induced T-
cell proliferation.  The mechanisms utilized by monocytic MDSCs to suppress T-cell 
proliferation involve Arg I activity and /or the production of NO [29].  Increased Arg I activity 
depletes L-arginine from the microenvironment, consequently inhibiting T-cell cycle progression 
[50], as well as downregulating CD3 expression [38].  Similarly, increased production of NO can 
limit T-cell proliferation through a mechanism involving inhibition of the IL-2 receptor 
downstream pathway [51].  The suppressive capability of granulocytic MDSCs has been 
attributed to the generation of ROS, which is also known to suppress antigen-induced T-cell 
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proliferation [29, 39, 40].  Consistent with these characterized features of MDSCs, we observed 
increased Arg I activity in splenocytes and significantly higher expression of iNOS and ROS 
generation in CD11b
+
 and CD11b
+
Ly6C
+
 cells in anti-APC mice, confirming the increased 
expansion and activation of the suppressive MDSC population in these mice. 
Several studies have demonstrated that in addition to suppressing T-cell function, 
MDSCs have the capacity to induce the generation of T-regs [52, 53].  The mechanism through 
which MDSCs induce T-reg expansion has yet to be fully elucidated; interestingly a study has 
implicated Arg I activity in MDSCs as a possible contributing factor in T-reg generation [42].  
Various studies have independently linked MDSCs to T-regs expansion.  For instance, the 
accumulation of T-regs within the tumor microenvironment has been associated to MDSCs, and 
in vitro studies have confirmed that MDSCs co-cultured with T-cells can result in T-reg 
expansion [52, 53].    In our study, we similarly observed that the expansion of CD11b
+
Ly6C
+
 
population in anti-PC mice was accompanied by an increase in T-reg subset, both in the CNS 
and in the periphery.  We further showed that co-culture of CD4
+
 T-cells with CD11b
+
 cells from 
anti-APC mice increased T-reg frequency.  These findings exhibit the increased suppressive 
capability of CD11b
+
 cells from anti-PC mice, not only via direct suppression of T-cell function 
but also through the induction of T-reg expansion. 
The accumulation of MDSCs is known to be critically mediated by the transcription 
factor, Stat3 [54, 55].  Inhibition of Stat3 signaling in vivo abrogated the expansion of MDSCs in 
tumor-bearing mice.  Moreover, the suppressive activities of MDSCs, specifically the generation 
of ROS, are also reportedly regulated by Stat3 [29].  Consistent with these studies, we observed 
increased Stat3 expression and Stat3 activation in the CD11b
+
Ly6C
+
 population in anti-PC mice, 
further confirming the MDSC phenotype of these cells.  
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The influence of APC on inflammatory settings can be mediated at two different fronts, 
namely APC’s direct effects on leukocytes and APC’s effects on vascular barrier permeability 
[3].  Consistently, we observed that inhibition of APC during EAE not only affected leukocyte 
function but additionally increased BBB permeability as evidenced by considerable leukocyte 
infiltration in the brains of anti-PC mice and the extensive perivascular cuffing observed in the 
brain parenchyma of these mice.  Despite exhibiting attenuated clinical symptoms, anti-PC mice 
had heavy cellular infiltrates in the brain, and the degree of infiltration is comparable to control 
mice with severe clinical symptoms.  Interestingly, cellular infiltration in the SC of anti-PC mice 
was less pronounced.  This deviates from the known pattern in classical EAE models, which is 
characterized by predominant infiltration and pathology in the SC [56, 57].  The reason for the 
disparity in infiltration between the two sites is unclear.  It should be noted, however, that there 
are reported molecular differences governing leukocyte trafficking events in the brain and in the 
SC [58].  Thus, it is likely that modulation of APC in the circulation can have separate and 
varying effects on leukocyte extravasation in the brain and SC, accounting for the observed 
disparity in cellular infiltration between the two sites. 
Despite considerable leukocyte infiltration in the brain, the pathological condition in the 
CNS of anti-APC mice, specifically demyelination and microglial activation, is minimal 
compared to control mice, and it follows that these mice exhibited attenuated clinical signs.  This 
is an indication that the infiltrating population in the CNS of anti-PC mice is less inflammatory.  
In fact, we observed increased T-reg frequency in the CNS of these mice, as well as increased 
production of anti-inflammatory cytokine, IL-10, from cellular infiltrates.  Further, we detected 
decreased pathogenic cytokines in the brains of anti-PC mice, specifically IFN-γ and IL-17, the 
signature cytokines produced by encephalitogenic CD4
+
 T-cell subsets in EAE.  We postulate 
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that the decreased encephalitogenic CD4
+
 T-cells in the CNS of anti-PC mice is a consequence 
of increased expansion of MDSCs in the periphery, which we have demonstrated can effectively 
suppress the effector responses of CD4
+
 T-cells, notably MOG35-55-induced proliferation of 
CD4
+
 T-cells, while concurrently inducing T-reg expansion.   
It is widely recognized that APC’s influences on the immune response, which is mediated 
through its direct regulation of leukocyte responses and its capability to confer vascular barrier 
protection, are pre-dominantly anti-inflammatory [3].  Therefore, it was largely unexpected that 
inhibition of APC during EAE resulted in the attenuation of disease.  We propose that depletion 
of APC, through its pleiotropic nature, affected EAE pathogenesis at multiple fronts, resulting in 
pathogenic conditions with opposing overall influences on the progression of EAE.  Specifically, 
APC inhibition resulted in increased BBB permeability as evidenced by increased dextran 
extravasation in the brain and leading to the considerable leukocyte infiltration in the brains of 
anti-PC mice.  This is in line with the well-documented effects of APC on vascular barrier 
function during pathogenic conditions [3].  Additionally, depletion of APC during EAE also 
affected the inflammatory responses of specific leukocyte populations.  APC’s ability to 
downregulate the pro-inflammatory responses of leukocytes has been notably observed in 
myeloid cells, with a recent study identifying the CD11b integrin as the facilitator of APC’s anti-
inflammatory effects on CD11b expressing myeloid cells [15].  Consistently, we observed that 
APC inhibition resulted in the increased frequency of the CD11b
+
 myeloid population.   We 
speculate that the absence of APC as a negative regulator resulted in the increased expansion and 
activation of various CD11b
+
 cells, including the suppressive MDSC population, during the EAE 
inflammatory setting.   It should be noted that MDSCs are known to expand in various 
inflammatory settings, including in EAE [39, 40].  It is likely that inhibition of APC contributed 
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to the further accumulation and activation of these cells as EAE progressed.  One likely 
mechanism through which APC can regulate MDSCs is through Stat3 expression.  Stat3 has 
been established to be critical in the expansion and suppressive activities of MDSCs [29].  In the 
study by Cao et. al, APC has been demonstrated to suppress the expression of Stat3 and in 
myeloid cells through engagement with the CD11b integrin [15].  Moreover APC can similarly 
downregulate the expression of iNOS, which is utilized in T-cell suppression by MDSCs [15].  It 
is likely, therefore, that APC inhibition can lead to increased expansion and activation of MDSC 
as observed in anti-PC mice, and consequently resulting in suppressed T-cell responses.  This, in 
effect, explains why inhibition of APC, generally known as an anti-inflammatory molecule, 
unexpectedly resulted in alleviated EAE severity.  APC inhibition increased BBB permeability 
and resulted in a more activated CD11b+ myeloid population, including a myeloid subset known 
to be a potent T-cell suppressor.  Since EAE is a pre-dominantly T-cell mediated disease, the net 
effect of APC depletion during EAE is alleviated disease severity (See proposed model Figure 
2.11). 
   APC’s influence on the MDSC population is presented here for the first time.  The 
ability of APC to affect the functional responses of MDSCs opens a novel therapeutic avenue 
through which APC can influence disease conditions.  MDSCs, for instance, are widely-reported 
to be a major hindrance in tumor immunity [59].  The findings in this study, which suggests that 
APC can negatively regulate MDSCs, bring to the fore, the possible therapeutic relevance of 
APC in cancer immunotherapies.   
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Figure 2.11 Proposed model.  Inhibition of APC results in increased expansion of CD11b
+
 cells, 
including the suppressive CD11b
+
 subset known as MDSCs.  The increased MDSCs mediate T-reg 
expansion and suppress T-cell proliferation through expression of Arg I, NO and ROS.  Inhibition of APC 
also resulted in increased BBB, however, since the effector T-cell population is diminished and the 
suppressive T-reg subset is increased, pathology and inflammation in the CNS is minimal.  
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CHAPTER 3 
Thrombin induces an inflammatory phenotype in a 
human brain endothelial cell line1 
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Abstract 
 
In this study, we utilized the human brain endothelial cell line, hCMEC/D3, to determine the 
effects of the coagulation factor, thrombin, on the human blood-brain barrier (BBB).  We show 
that thrombin increased the mRNA and cell surface levels of ICAM-1 and VCAM-1 in 
hCMEC/D3 cells.  Thrombin similarly upregulated several chemokines implicated in human 
neurological conditions.  Additionally, the paracellular permeability of the human BBB in vitro 
was increased following thrombin treatment.  Overall, this study demonstrates that thrombin can 
effectively induce an inflamed phenotype in an in vitro human BBB, suggesting the potential 
relevance of thrombin in neuroinflammatory diseases such as multiple sclerosis, wherein 
leukocyte extravasation into the CNS as a consequence of increased BBB permeability is a 
primary pathological component. 
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Introduction 
The blood-brain barrier (BBB) is structured to limit the influx of potentially harmful 
blood-borne molecules into the CNS.  The BBB endothelium, however, is responsive to various 
stimuli resulting in a BBB phenotype that can dynamically change based on the conditions in the 
microenvironment [1].  In neuroinflammatory settings, for instance, an inflamed BBB becomes 
more permeable to leukocytes in the circulation as a consequence of phenotypic changes that 
include the disassembly of tight junction molecules, increased expression of cell adhesion 
molecules (CAMs), and synthesis of chemotactic molecules [1, 2].   
 In recent years, there has been accumulating evidence of a complex, two-way interaction 
between the immune and coagulation systems [3, 4].  Specific components of the coagulation 
system can directly influence the immune response.  The coagulation factor, thrombin, in 
particular, is widely-regarded to have a major influence on inflammation [5-7].  Thrombin is a 
serine protease that is responsible for the formation of fibrin, the primary component of blood 
clot [8].  Beyond its central role in the coagulation process, thrombin can directly affect the 
cellular processes of various cell types, including leukocytes and endothelial cells, largely 
through the activation of G protein-coupled receptors known as protease-activated receptors 
(PARs) [9, 10].  
 While the inflammatory influences of thrombin have been predominantly observed in the 
periphery, there are now growing reports that thrombin may also be involved in 
neuroinflammatory and neurodegenerative conditions [11, 12].  Thrombin in the circulation can 
enter the CNS in conditions where the BBB is compromised [13].  Additionally several 
coagulation factors including prothrombin and its activator, factor X, are locally synthesized in 
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the brain [14, 15].  Increased thrombin activity and/or expression in the CNS have been observed 
in a number of neurological diseases.  It has been reported that there is increased thrombin 
inhibitors in the CNS and in the periphery during experimental autoimmune encephalomyelitis 
(EAE), the animal model for multiple sclerosis (MS).  In Parkinson’s disease and human 
immunodeficiency virus encephalitis, thrombin and prothrombin expression have been shown to 
be upregulated in astrocytes and neurons [16, 17].  Ischemic brains are characterized by high 
thrombin levels as a result of thrombin extravasation from the circulation and local prothrombin 
synthesis [18, 19].  Elevated thrombin levels have also been observed in brain microvessels in 
Alzheimer’s disease [20].  While the specific role of thrombin in the progression of these 
diseases is still not well-delineated, it is known that resident cells in the CNS can be responsive 
to thrombin activity.  Thrombin can induce microglia and astrocytes to release proinflammatory 
cytokines including IL-1β, IL-6, and TNF-α [17, 21].  High thrombin concentrations can also 
result in neurodegeneration [22].      
 Similarly, in vivo studies in animal models have shown that the BBB can be responsive to 
high levels of thrombin in the CNS.  For instance, intrathecal injection of thrombin into rat brains 
can result in brain edema as a result of BBB permeability [23, 24].  The collective effects of 
thrombin on the phenotype of the specialized endothelial cells that comprise the human BBB 
however have not been thoroughly investigated.  While there are a number of studies that have 
examined thrombin’s effects on endothelial cells, these studies have exclusively utilized 
endothelial cells from the periphery.  The specific responses of peripheral endothelial cells to 
thrombin, however, may not necessarily reflect the responses of the distinct endothelial cells that 
comprise the BBB.  It is, therefore, warranted to particularly investigate the effects of thrombin 
activity on brain endothelial cells.  Furthermore, given that thrombin’s presence is heightened in 
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various human neuroinflammatory and neurological disorders it is pertinent to study thrombin’s 
effects specifically on human brain endothelial cells. 
 The purpose of this study is to utilize a recently developed in vitro model of the human 
BBB to examine the responses of human brain endothelial cells to thrombin activity.  We utilized 
the hCMEC/D3 cell line, an immortalized primary human brain endothelial cell line that stably 
retain the morphological characteristics of the BBB without the need for supporting glial cells 
[25], as an in vitro model for studying the responses of human brain endothelial cells to 
thrombin.  In this study, we show that thrombin induces specific responses in brain endothelial 
cells in vitro, effectively inducing an inflamed BBB phenotype that is conducive to the potential 
recruitment, capture, and diapedesis of leukocytes.  The results of this study may provide insight 
into the possible contribution of thrombin in the pathogenesis of neuroinflammatory and 
neurodegenerative conditions. 
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Materials and methods 
Cell Culture 
 The hCMEC/D3 cell line was generated by Weksler et.al [25] and kindly provided to us 
by Dr. Babette Weksler.  The cells were cultured in EBM-2 (Lonza, Wokingham UK) or MCDB 
131 (Invitrogen, CA U.S.A) with 2.5% fetal bovine serum (FCS) and supplemented with 
hydrocortisone, ascorbate, basic fibroblast growth factor (bFGF), vascular endothelial growth 
factor (VEGF), insulin-like growth factor (IGF-1), epidermal growth factor (EGF), and 
gentamycin sulfate.  Supplements were purchased from Lonza (Wokingham, UK), and 
concentrations used were according to the manufacturer’s protocol.  The cells were maintained at 
37
o 
C in a humidified atmosphere with 5% CO2.  All culture wares were coated with 0.1 mg/ml 
rat-tail collagen type I (BD Pharmingen, CA U.S.A.).  In all the experiments, the cells were 
grown to confluency for 7-10 days in fully supplemented MCDB-131 or EBM-2 media, which 
was changed every 2-3 days.  Eighteen to twenty hours before each assay, the media was 
switched to reduced FBS and growth-factor depleted medium (MCDB 131 or EBM-2 
supplemented with 0.25% FBS, 1 ng/ml bFGF, 10 mM Hepes, and .55 µM hydrocortisone).  
This media was used throughout the entire duration of all experiments.  For thrombin treatments, 
human thrombin (Sigma-Aldrich MO, U.S.A.) was solubilized in molecular grade H2O and 
further diluted in media.   
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Quantitative real-time PCR 
 Cells were seeded on collagen-coated 12-well plates (BD Falcon, CA U.S.A).  After 
thrombin (0.5 – 60 U/ml) or vehicle treatments, total RNA was extracted using Trizol (Invitrogen 
CA, U.S.A) according to the manufacturer’s protocol.  Extracted RNA was treated with 
Baseline-Zero DNAse (Epicentre, WI U.S.A.) to remove contaminating genomic DNA.  1.5 µg 
of total RNA was reverse transcribed using High-Capacity cDNA Reverse Transcription kit 
(Applied Biosystems CA, USA).  Real Time PCR was performed using SYBR Green technology 
(SYBR FAST Master Mix KAPAbiosystems, MA U.S.A) on a CFX96 Real Time System 
Thermal Cycler (Bio-RAD, CA U.S.A).  The cycling conditions were as follows:  Enzyme 
activation 95° C for 3 minutes followed by 40 cycles of denaturation 95°C for 3 secs, annealing 
60° C for 30 seconds, elongation 72° C for 5 seconds.  BioRad CFX Manager software was used 
to determine cycle threshold (Ct) values, and gene expression levels were calculated using the  
2
-∆∆Ct
 method.  The expression levels of all genes of interest were normalized to the internal 
control gene, GAPDH.   
 
Flow Cytometry Analysis 
 Cells were seeded on 24-well plates (BD Falcon).  After thrombin or vehicle treatments, 
cells were gently detached from culture plates using polyethylene cell scrapers (BD Falcon).  
The cells were washed and re-suspended in staining buffer (PBS with 0.5% BSA, and 0.09% 
sodium azide).  Cell suspensions were incubated with antibody against the protein of interest for 
30 minutes at 4
o
C.  Antibodies used are as follows: biotin anti-human ICAM-1, (BD 
Pharmingen, CA USA), APC-conjugated anti-human VCAM-1 (Biolegend, CA U.S.A), anti-
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human PAR-1 (Enzo Life Sciences, NY U.S.A).  The cells were subsequently washed twice in 
staining buffer and incubated with the appropriate secondary antibody for 30 minutes at 4
o
C.  
The cells were subjected to two final rounds of washing and resuspended in a final volume of 
300 µl of staining buffer.  The cells were acquired using a FACSCanto II flow cytometer (BD 
Biosciences, CA U.S.A).  The raw data was evaluated using FlowJo Flow Cytometry Analysis 
Software (Treestar, OR U.S.A). 
 
Western Blot Analysis 
 Cells were seeded on collagen-coated 12-well plates (BD Falcon).  After thrombin or 
vehicle treatments, the supernatants and whole-cell lysates were collected.  Cells were lysed on 
ice using lysis buffer (10 mM Tris-HCl, pH 7.4, 150mM NaCl, 1 mM EDTA, 10 mM Na3VO4, 
10 mM Sodium Fluoride, 10 mM Sodium Pyrophosphate, 1% NP-40, 1mM PMSF, 1µM 
Pepstatin A).  Laemmli buffer at 5x (60 mM Tris-HCl pH 6.8, 2% SDS, 10% glycerol, 5% β-
mercaptoethanol, 0.01% bromophenol blue) was added to the supernatant and whole-cell lysate 
samples.  Samples then were heated to 99°C for 5 minutes.  For detection of CCL2 or CXCL8, 
the supernatant samples were loaded in 18% SDS-PAGE gel (1.5 M Tris-HCl pH 8.8, 20% SDS, 
Acrylamide/Bis-acrylamide, 10% ammonium persulfate, TEMED).  For CX3CL1 detection, the 
whole-cell lysate samples were loaded in 7% SDS-PAGE gel.  The gels were ran in running 
buffer (25mM Tris, 192 mM glycine, 0.1% SDS pH 8.5) at 100 V.  Proteins were transferred to 
nitrocellulose membrarane (Whatman, NJ USA) by standard wet transfer protocol.  After 
transfer, membranes were washed with TBS-Tween (100mM Tri-HCl pH 7.5, 0.9% NaCl, 0.1% 
Tween-20) for 5 minutes.  Membranes were blocked with 5% BSA in TBS-Tween for 1 hour at 
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4°C.  After blocking, membranes were incubated with primary antibody in 1% BSA in TBS-
Tween overnight at 4°C.   Primary antibodies used are as follows: rabbit anti-human IL-8 
(Peprotech NJ, USA), rabbit anti-human MCP-1 (Hycult Biotech, USA), rat anti-mouse 
CX3CL1 (R&D Systems).  Membranes were washed 3 times with TBS-Tween and incubated 
with the appropriate HRP-conjugated secondary antibody for 1 hour at room temperature.  
Membranes were washed 3 times with TBS-Tween and incubated with chemiluminescent 
substrate for HRP (Thermo Scientific Super Signal).  X-ray films were exposed to membranes to 
visualize proteins.      
 
Transendothelial Electrical Resistance Measurement 
Cells were seeded on collagen-coated transwell polyester membrane inserts (for 24-well 
plate) with 8 µm pore size (BD Falcon).  Transendothelial Electrical Resistance (TEER) was 
measured using volt ohm meter, EVOMX, equipped with STX100 electrodes (World Precision 
Instruments, FL USA).  TEER readings were recorded 10 minutes before thrombin (5, 20, 60 
U/ml) or vehicle treatment and every ten minutes for 1.5 hours after treatments.  Cells were 
maintained on a 37°C heat block for the duration of the TEER measurements.  Changes in TEER 
at the given timepoints were expressed as fold change relative to TEER readings that were 
recorded 10 minutes before treatment. 
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 FITC-Dextran Permeability Assay 
 hCMEC/D3 cells were grown to confluence on collagen-coated transwell inserts (for 24-
well plate) with 3 µm pore size (BD Falcon).  Thrombin at 5, 20, 60 U/ml, or vehicle and 1 
mg/ml of FITC-dextran in assay media were added to the apical chamber.  The media from the 
basolateral lower chamber was sampled after 15, 30, 60, 90, and 180 minutes of treatment to 
assess the degree of FITC-dextran flux across the endothelial barrier.  Fluorescence intensity was 
measured at excitation wavelength 488 nm and at emission wavelength 519 nm using Synergy 4 
microplate reader (Biotek, VT U.S.A).  The degree of diffused FITC-dextran at each given 
timepoint was expressed as fold change in fluorescence intensity relative to media from vehicle 
controls.     
    
Statistical Analysis 
Results were represented as means + S.E.  All experiments were done in triplicates.  
Two-tailed student’s T-test was used to analyze the differences between two groups using 
GraphPad Software.  A difference was considered statistically significant if the p value is < 0.05.  
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Results 
The hCMEC/D3 cell line expresses the necessary receptors to be responsive to thrombin 
To determine whether hCMEC/D3 cells can be responsive to thrombin activity, we 
examined whether these cells constitutively express the cellular receptors for thrombin.  We 
show by real-time quantitative PCR that hCMEC/D3 cells express all four PARs, three of which 
(PAR-1, PAR-3, and PAR-4) can be activated by thrombin (Figure 3.1A).  PAR-1, the 
predominant thrombin receptor on endothelial cells [26], is the most highly expressed among all 
three thrombin receptors in hCMEC/D3 cells.  Additionally, we confirmed by flow cytometry 
analysis that hCMEC/D3 cells express PAR-1 at the cell surface (Figure 3.1A).  We also 
examined whether cell surface expression of PAR-1 is altered in response to thrombin activity.  
We observed a slight decrease in PAR-1 expression after 1.5 hours of thrombin treatment (Figure 
3.1B).  At 3 hours, PAR-1 levels returned to baseline and remained close to these levels until 20 
- 24 hours of thrombin treatment.  After 24 hours of thrombin treatment, we observed a 
significant decrease in cell surface expression of PAR-1 (Figure 3.1B).  These data show that 
thrombin can affect the expression of PAR-1 on hCMEC/D3 cells and is consistent with previous 
studies on other endothelial cell systems [27].  We also show that the hCMEC/D3 cell line 
express thrombomodulin and endothelial protein C receptor (EPCR) (Figure 3.1C).  Both 
receptors are involved in regulating thrombin activity; the former acts as a thrombin regulator 
through direct interactions with thrombin, while the latter is involved in the activation of protein 
C, a serine protease known to inhibit thrombin activation [28].  Overall, these data show that the 
hCMEC/D3 cells express the necessary receptors to respond to thrombin activity. 
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Figure 3.1  hCMEC/D3 cells express the necessary receptors to respond and regulate thrombin 
activity.  A) Real-time quantitative PCR was performed to assess the expression of PARs in 
hCMEC/D3 cells.  The mRNA levels are expressed relative to the internal control gene, 
GAPDH.  Data are represented as means + S.E. (n=3).  Fluorescence histogram on the right 
represents hCMEC/D3 cells that were stained with either fluorescently-labeled antibody to PAR-
1 or isotype control.  Cell fluorescence was assessed by flow cytometry.  B) hCMEC/D3 cells 
were stained with fluorescently-labeled antibody to PAR-1 after treatment with 20 U/ml of 
thrombin for the timepoints given.  Cell fluorescence was examined by flow cytometry, and 
levels of cell surface PAR-1 at each timepoint was shown as fold change in mean fluorescence 
intensity relative to vehicle controls.   Data represented as means + S.E. (n = 3).  * p < 0.05 
versus vehicle control (two-tailed Student’s t-test).  Fluorescence histogram on the right 
represents cell surface expression of PAR-1 at 24 hours after vehicle or thrombin treatment.  C) 
The mRNA expression of thrombomodulin and EPCR was examined by real-time quantitative 
PCR.  The mRNA levels are expressed relative to the internal control gene, GAPDH.  Data are 
represented as means + S.E. (n=3). 
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Thrombin induces brain endothelial cells to increase the mRNA and cell surface expression of 
ICAM-1 and VCAM-1   
The BBB can increase the expression of cell adhesion molecules (CAMs) in response to 
stimulating factors in the microenvironment.  The resting BBB typically expresses low levels of 
CAMs, however in certain conditions such as in neuroinflammatory settings, the BBB 
upregulates various CAMs to capture inflammatory immune cells and facilitate the entry of 
leukocytes into the CNS [29].  ICAM-1 and VCAM-1 are believed to have a predominant 
involvement in leukocyte infiltration into the CNS [29].  We examined whether thrombin is 
capable of altering the expression of both ICAM-1 and VCAM-1 in human brain endothelial 
cells.  Our data show that thrombin can induce a dose-dependent increase in mRNA expression 
of both CAMs in hCMEC/D3 cells (Figure 3.2A).  The increase in mRNA levels reached 
statistical significance after treatment with thrombin at 0.5 U/ml, the lowest concentration used, 
and reached maximal upregulation after treatment with 60 U/ml of thrombin.  The increase in 
adhesion molecule expression was observed after one hour of thrombin treatment and further 
increase was observed at three hours (Figure 3.2B).  The mRNA levels return close to basal 
levels after six hours of thrombin treatment.  We observed a second increase in mRNA levels 
after 18 hours of treatment, subsequently declining to basal levels at 24 hours (Figure3.2B). 
We next examined whether the cell surface levels of both CAMs are similarly increased 
after thrombin treatment.  Flow cytometry analysis shows detectable increase in VCAM-1 cell 
surface expression after 24 hours of thrombin treatment (Fig 3.2C, left).  The up-regulation in 
cell surface VCAM-1, as demonstrated by increase in mean fluorescence intensity (MFI), is 
observed after treatment with thrombin concentrations in the range of 0.5 – 10 U/ml (Figure 
3.2C, right).  Higher concentrations of thrombin (20 – 60 U/ml), however, decreased cell surface 
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VCAM-1 expression at 24 hours (Figure 3.2C, right).  Conversely, we observed maximal 
increase of ICAM-1 cell surface levels at 24 hours with higher concentrations of thrombin (20-40 
U/ml) (Figure 3.2D). We did not observe significant changes in cell surface ICAM-1 after 
treatment with lower concentrations of thrombin (data not shown).  Overall these data 
demonstrate that thrombin can effectively induce brain endothelial cells to express VCAM-1 and 
ICAM-1, both at the mRNA and cell surface levels.   
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Figure 3.2   Thrombin upregulates the mRNA and cell surface expression of VCAM-1 and 
ICAM-1 in human brain endothelial cells.  A)  hCMEC/D3 cells were activated for 3 hours with 
thrombin at the given concentrations, and the mRNA expression of VCAM-1 and ICAM-1 were 
assessed by real-time quantitative PCR.  Expression levels are shown as fold change relative to 
vehicle-treated controls.  Data represented as means + S.E. (n = 3). * P < 0.05, versus vehicle 
control (two-tailed Student’s t-test).  B)  hCMEC/D3 cells were treated with 10 U/ml of thrombin 
for the given timepoints.  The mRNA expression levels of adhesion molecules at each timepoint 
were evaluated by real-time quantitative PCR.  Mean expression levels are shown as fold change 
relative to vehicle treated controls for each given time point (n=3).  C) and D)  hCMEC/D3 cells 
were stained with fluorescently-labeled antibodies to VCAM-1 and ICAM-1 after treatment with 
the given concentrations of thrombin for 24 hours.  Cells were analyzed by flow cytometry, and 
changes in cell surface expression of VCAM-1 and ICAM-1 were assessed by comparing mean 
fluorescence intensity (MFI) of thrombin-treated samples to vehicle-treated controls.  
Fluorescence histograms for VCAM-1 and ICAM-1 are shown on the left.  Bar graphs on the 
right show fold change in MFI relative to vehicle treated controls.  Data represented as means + 
S.E. (VCAM-1 n = 3, ICAM-1 n = 3).  * P < 0.05 versus vehicle control (two-tailed Student’s t-
test).   
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Thrombin induces brain endothelial cells to increase the expression of chemokines 
Under pathological conditions, the endothelial cells that form the BBB can synthesize 
chemokines to recruit leukocytes to the site of CNS inflammation [30].  In addition to their 
chemotactic functions, chemokines secreted by endothelial cells can enhance leukocyte firm 
adhesion to CAMs on the endothelium, thus directly facilitating the subsequent diapedesis of 
leukocytes to the CNS parenchyma [29].  We examined whether thrombin can induce CNS 
endothelial cells to express chemokines that are known to be involved in various 
neuroinflammatory conditions.  We examined the expression of CXC chemokines, a family of 
chemokines known to be primarily chemotactic for neutrophils.  In particular, we looked at the 
mRNA expression of CXCL1 (GRO-alpha), CXCL2 (GRO-beta), CXCL8 (IL-8), and CXCL10 
(IP-10); all have been reportedly involved in various neuropathologies [31, 32]. Thrombin 
activity significantly resulted in increased mRNA expression of all four CXC chemokines 
(Figure 3.3A).  CXCL8 a strong neutrophil chemoattractant, with likely involvement in 
neurological conditions like MS, ischemic brain injury and traumatic brain injury [33], was the 
most highly upregulated with maximal mRNA upregulation reaching 40 fold.  Western blot 
analysis confirms a time-dependent increase in soluble CXCL8 in the supernatant of thrombin 
treated hCMEC/D3 cells (Figure 3.3B). 
We also examined the mRNA expression of selected members of the CC chemokine 
family which have been recognized to play roles in neuroinflamatory diseases; these include 
CCL2 (MCP-1), CCL3 (MIP-α), and CCL5 (RANTES) [30].  Thrombin can induce a robust 
dose-dependent increase in mRNA levels of CCL2 (Figure 3.3C), a potent chemoattractant for 
monocytes and activated T cells [33].  CCL2 mRNA expression was increased by 15.2 fold after 
treatment with 60 U/ml of thrombin.  Additionally, soluble CCL2 was also increased over time 
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in the supernatant of thrombin treated hCMEC/D3 cells (Figure 3.3D).  Thrombin treatment, 
however, did not significantly affect the mRNA expression of either CCL3 or CCL5 (Figure 
3.3C).   
We next examined the CX3C chemokine group, which is comprised of CX3CL1 
(fractalkine).  CX3CL1 is a unique chemokine in that it is synthesized as a membrane-bound 
molecule allowing it to directly capture circulating leukocytes.   It can also be cleaved from the 
cell membrane by metalloprotenaises to generate a soluble form that can function as a traditional 
chemoattractant [34].  CX3CL1 has similarly been linked to the pathogenesis of several 
neuroinflammatory diseases, including Parkinson’s disease and experimental autoimmune 
encephalomyelitis (EAE) [35].  Our data show that thrombin activity can dose-dependently 
induce brain endothelial cells to significantly upregulate the mRNA expression of CX3CL1 
(Figure 3.3E).  The highest upregulation was observed at 9.3 fold relative to vehicle control.  We 
also show that CX3CL1 protein expression was increased by thrombin in whole-cell lysates of 
hCMEC/D3 cells (Figure 3.3F). 
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Figure 3.3  Thrombin induces the expression of neuroinflammatory-implicated chemokines in 
human brain endothelial cells.  hCMEC/D3 cells were activated with the given concentrations of 
thrombin for three hours, and the mRNA levels of selected chemokines from A) CCL, C) CXC, 
and E) CX3C chemokine families were assessed by real time quantitative PCR.  The mRNA 
levels are expressed as fold change relative to vehicle treated controls.  Data represented as 
means + S.E. (n = 3). *P < 0.05 versus vehicle controls (two-tailed Student’s t-test).  Arrows 
span the concentrations in which the chemokines indicated have been significantly upregulated.  
B) and D) The supernatant of thrombin-treated hCMEC/D3 cells at the given timepoints were 
examined by western blot for soluble CXCL8 or soluble CCL2 .  F) The protein expression of 
CX3CL1 in whole-cell lysates of thrombin-treated hCMEC/D3 cells was assessed by western 
blot. 
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Thrombin increases the paracellular permeability of brain endothelial cells.  
One of the more drastic changes in BBB functionality in response to factors in the 
microenvironment is the increased permeability to cells and compounds in the circulation [1].  
Increase in BBB permeability is a consequence of various processes in endothelial cells which 
include cytoskeletal rearrangements and disassembly of junctional proteins, ultimately resulting 
in the formation of spaces in between endothelial cells to allow for paracellular diapedesis of 
leukocytes and paracellular flux of blood-borne molecules [29].  We also examined if thrombin 
activity can directly affect the permeability of the human BBB in vitro.  We assessed 
permeability changes by measuring the transendothelial electrical resistance (TEER) of 
hCMEC/D3 cells after thrombin treatment.  The cells were seeded in transwell inserts and treated 
with vehicle or thrombin at 5, 20, or 60 U/ml.  TEER was measured over time before and after 
treatment; a decrease in TEER correlates with increase in barrier permability.  Thrombin at all 
three concentrations resulted in detectable decrease in TEER of hCMECD/3 cells within 30 
minutes after treatment (Figure 3.4A).  Maximal and statistically significant TEER decrease was 
observed after 1 hour of treatment at all three concentrations.  We also observed that the decrease 
in TEER was not sustained; as TEER started to increase 70 minutes after treatment (Fig 3.4A).  
The paracellular permeability of thrombin-treated hCMEC/D3 cells was further 
investigated by assessing the paracellular flux of 10 kDa FITC-Dextran at various timepoints 
after treatment with thrombin.  We observed statistically significant increases in dextran 
permeability 15 minutes after thrombin treatment at 5, 20, 60 U/ml (Figure 3.4B).  Maximal 
permeability was observed after 60-90 minutes of treatment.  We did not observe continued 
increase in dextran permeability at 3 hours (180 minutes) (Figure 3.4B), suggesting that similar 
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to what was observed with TEER measurement, the increased paracellular permeability to 
dextran molecules was not sustained for prolonged periods.         
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Figure 3.4.  Thrombin increases the paracellular permeability of human brain endothelial cells.  
A) hCMEC/D3 cells were seeded on transwell inserts and treated with vehicle or thrombin at 5, 
20, or 60 U/ml.  Permeability was assessed by measuring TEER changes every 10 minutes after 
treatment.  TEER changes at each given timepoint are shown as fold change relative to TEER 
readings recorded 10 minutes prior to treatment.  Data represented as means + S.E. (n = 3).  *P < 
0.05 versus vehicle control at each timepoint (two-tailed Student’s t test).  B) hCMEC/D3 cells 
were seeded in transwell inserts; 10 KDa FITC-dextran and thrombin at the concentrations 
shown were added to the apical chamber.  After treatment, media from the lower chamber were 
sampled at the timepoints given to assess the degree of FITC-dextran paracellular flux.  
Fluorescence intensity in the basolateral media is expressed as fold change relative to vehicle 
control for each respective timepoint.   Data represented as means + S.E. (n = 3) * P < 0.05 
versus vehicle control at each timepoint (two-tailed Student’s t test).   
 
 
 
 
 
109 
 
Discussion 
There are growing reports that thrombin, the central enzyme in the coagulation process, is 
increased in the CNS during various neuroinflammatory and neurodegenerative disorders [11, 
12].  In this study, we investigated whether increased thrombin presence in the CNS can 
potentially affect the phenotype and functionality of the BBB.  We utilized the hCMEC/D3 cell 
line, a recently-developed model of the human BBB [25], to assess the collective effects of 
thrombin on brain endothelial cells.   We demonstrate that thrombin can induce the expression of 
chemokines and CAMs in hCMEC/D3 cells.  These results corroborate previous studies that 
have been conducted on peripheral endothelial cells [36, 37].  There is, however, an apparent 
difference in the degree of thrombin responsiveness in human brain endothelial cells compared 
to what has been reported on peripheral endothelial cells.  A study conducted on human 
umbilical vein endothelial cells (HUVECS) reported seeing robust mRNA upregulation of 
ICAM-1 (16.0 fold), and VCAM-1 (12.2 fold) after treatment with a relatively low dose of 
thrombin (2 U/ml for four hours) [37].  In comparison, our study showed that hCMEC/D3 cells 
reached a comparable level of mRNA upregulation after treatment with 60 U/ml of thrombin. 
The upregulation in ICAM-1 and VCAM-1 cell surface levels were similarly reported to be more 
robust in thrombin-treated HUVECS [36] compared to what we observed in hCMEC/D3 cells.  It 
has been proposed that cells detect and respond to differences in thrombin concentrations based 
on the rates of receptor activation [38].  The observation that HUVECS are more responsive that 
hCMEC/D3 cells to thrombin at low concentrations suggests that thrombin receptors on 
HUVECS are likely being activated at a faster rate than on hCMEC/D3 cells.  Any differences in 
the expression levels of thrombin receptors on the two cell systems may likely affect the rate of 
receptor activation.  Moreover, thrombomodulin, a cell surface glycoprotein expressed on 
110 
 
endothelial cells, including hCMEC/D3 cells (Figure1C) and HUVECS [39], is known to 
neutralize the pro-coagulant and pro-inflammatory activities of thrombin.  Differences in 
thrombomodulin cell surface levels on hCMEC/D3 cells and HUVECS may also affect the 
activation rate of thrombin receptors on both cell types.  It should be noted, however, that while 
hCMEC/D3 cells may be less responsive than HUVECS to thrombin activity, the thrombin-
induced cell surface levels of VCAM-1 (1.8 fold) and ICAM-1 (1.7 fold) on hCMEC/D3 are 
levels that have been shown to be biologically functional.  Recent studies by Roh et al. [40] and 
Rains et al. [41] show that a 1.25 to 2 fold increase in ICAM-1 expression on endothelial cells 
resulted in increased monocyte adhesion.  Another group [42] showed that a 2 fold increase in 
VCAM-1 cell surface levels is likewise sufficient to increase monocyte adhesion.      
While HUVECS and hCMEC/D3 may differ in the degree of thrombin responsiveness, 
our data showed that the two cell systems likely have similar mechanisms for clearance of 
activated thrombin receptors and re-expression of new intact receptors.  In HUVECS, activation 
of thrombin receptors results in rapid internalization of receptors, resulting in 60% clearance of 
cleaved receptors within 10 minutes [27].  Moreover, HUVECS have intracellular pools of new 
thrombin receptors, allowing for immediate re-expression of new receptors on the cell surface 
[27].  HUVECS can restore nearly a full set of new receptors within a few hours after the initial 
thrombin receptor activation and clearance [27].  In hCMEC/D3 cells, PAR-1 surface expression 
decreased after treatment with thrombin for 1.5 hours, suggesting that similar to HUVECS, 
hCMEC/D3 likely internalize thrombin receptors immediately after activation.  We also 
observed that PAR-1 cell surface expression returned to basal levels within three hours of 
thrombin activation, suggesting that hCMEC/D3 cells like HUVECS have an existing 
intracellular pool of new receptors that can immediately replace activated and internalized 
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receptors.  Treatment of hCMEC/D3 cells for various timepoints longer than 3 hours did not 
significantly alter cell surface levels of PAR-1, likely due to the continued process of receptor 
internalization and receptor re-expression.  We did eventually observe a significant decrease in 
PAR-1 expression after 24 hours of continued thrombin treatment, which may suggest that, at 
this point, the intracellular reserve of intact receptors have been depleted.   
We investigated whether thrombin can affect the paracellular permeability of brain 
endothelial cells.  For the endothelium to be permissive to paracellular diapedesis, endothelial 
cells must undergo various processes which include cytoskeletal rearrangements and disassembly 
of junctional proteins, ultimately resulting in the formation of spaces in between endothelial cells 
to allow for paracellular transmigration [43].  We assessed if thrombin can affect the paracellular 
permeability of brain endothelial cells by measuring TEER changes and permeability to dextran 
molecules after thrombin treatment.  We observed that thrombin can rapidly but transiently 
increase the paracellular permeability of brain endothelial cells.  These observations are 
consistent with previous studies on peripheral endothelial cells [44].  Increases in endothelial 
permeability in response to thrombin activity have been attributed to the disassembly and 
disappearance of junctional proteins at cell to cell contacts [43].  The thrombin-induced 
retraction of junctional proteins, however, is not accompanied by protein degradation, and thus 
can be rapidly reversible [44].  This is the likely mechanism behind the transient permeability 
observed in thrombin-treated hCMEC/D3 cells. 
Thrombin’s effects on endothelial permeability and CAM expression are known to be 
mediated through different signaling pathways and therefore subject to different regulatory 
mechanisms [26, 43].  This may explain why thrombin at certain concentrations can have 
opposing effects on CAM expression and paracellular permeability.  For instance, we observed 
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that thrombin at 60 U/ml rapidly resulted in increased permeability in hCMEC/D3 cells, but this 
same concentration decreased the expression of cell surface VCAM-1 at 24 hours (Figure 2C 
right).  Thrombin induction of VCAM-1 expression is mediated through the NF-κB signaling 
pathway, specifically the p65 subunit of NF-κB [26].  However, it has also been observed that 
thrombin can induce the p50 subunit of NF-κB, which has been suggested to be a negative 
transcriptional regulator of the VCAM-1 gene [26].  Thus, it has been proposed that there is a 
possible negative-feedback mechanism in the thrombin-VCAM-1 signaling pathway [26].  The 
observed downregulation of VCAM-1 at higher concentrations of thrombin is likely due to this 
negative feedback mechanism.            
The overall effect of thrombin on brain endothelial cells in vitro results in an endothelium 
phenotype that is conducive to the multiple stages of leukocyte extravasation.  The question 
remains whether thrombin can have the same effects on the BBB in vivo.   Previous studies have 
shown that intracerebroventricular injection of thrombin into rat brains resulted in increased 
brain edema [45], suggesting that thrombin is capable of affecting the functionality of the BBB 
in vivo.  It remains to be seen, however, if in vivo thrombin activity can result in increased 
leukocyte extravasation into the CNS.  Furthermore, the source of endogenous thrombin that can 
affect the BBB during neurological diseases also needs to be considered.  While thrombin is 
predominantly found in the circulation, thrombin can be locally synthesized in the CNS [14].  
Moreover, thrombin activity and/or expression have been shown to be increased in the CNS in a 
number of neurological diseases [12].  The fact that intracerebroventricularly-injected thrombin 
in rat brains can affect BBB permeability [24], suggests that thrombin from within the CNS is 
capable of affecting BBB function.  Thus, it is possible for thrombin synthesized within the CNS 
to induce the phenotypic changes in brain endothelial cells that have been shown in this current 
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study.  Additionally, it also needs to be taken into account that thrombin can induce glial cells to 
produce pro-inflammatory cytokines such as IL-1β and TNF-α [13], which are cytokines that 
have been traditionally implicated in BBB dysfunction [46].   While we have shown in this study 
that thrombin can independently affect the functionality of the BBB, it is very likely that 
thrombin can act in concert with various pro-inflammatory factors during neurological 
conditions to affect BBB functionality.  In fact, it has been observed that thrombin and TNF-α 
can synergistically affect endothelial barrier function in vitro [47]. 
In summary, this study shows that thrombin can induce brain endothelial cells to express 
chemokines and CAMs, which can potentially augment the recruitment and capture of 
leukocytes from the circulation.  In addition, thrombin can increase the paracellular permeability 
of brain endothelial cells, resulting in a BBB that is more permeable to leukocyte diapedesis.  
Therefore, thrombin can modify the functionality of brain endothelial cells in vitro, resulting in a 
BBB phenotype that can likely facilitate the successive stages of leukocyte extravasation.  
Overall, this current study lends better understanding to the implications of increased thrombin 
presence in the CNS on the pathology of neurological conditions.     
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Previous studies have demonstrated that coagulation components are effective regulators 
of the immune response [1-3].  Ongoing interest lies in determining the influence of coagulation 
factors on the pathogenesis of specific disease conditions, which may potentially lead to the 
formulation of novel therapeutic strategies.  There is already a well-known involvement of 
coagulation components, specifically the anticoagulant, APC, on the systemic inflammatory 
condition, sepsis [4], leading to the development of a novel, albeit controversial, sepsis treatment 
[5, 6].  Moreover, there are convincing studies linking coagulation factors to other disease 
conditions [4, 7].  Strong indications suggest the activation of the coagulation system during 
disease progression in several neuroinflammatory conditions, including MS and EAE [7-9].  The 
specific mechanisms on how coagulation components affect MS and EAE progression, however, 
are still unclear.  In this dissertation, we described the influence of endogenous APC on disease 
development and pathogenesis of EAE, the animal model for MS.  We demonstrated that 
modulating APC levels in the circulation affected disease pathogenesis at multiple fronts, 
increasing BBB permeability but also concurrently altering the functional responses of leukocyte 
populations.  Particularly, the effector functions of CD4
+
 T-cells are diminished, consequently 
resulting in attenuated disease progression.   We additionally described the direct inflammatory 
effects of the coagulation factor, thrombin, on an in vitro model of the human BBB.  Our study 
exhibited that thrombin effectively modified the BBB, resulting in a phenotype that is conducive 
to leukocyte recruitment and extravasation.  BBB permissiveness to leukocyte extravasation is 
one of the major pathological components of MS and EAE [10-12]; this particular study, 
therefore, pinpoints thrombin’s potential influence on the progression of these 
neuroinflammatory diseases.  Overall, the findings described in this dissertation unequivocally 
demonstrate the capacity of coagulation factors in effectively influencing pathogenic components 
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of EAE and MS, and further affirms that the dynamic interactions between the coagulation and 
immune systems can affect disease pathogenesis and progression. 
We inhibited APC activity in the circulation during EAE through administration of an 
antibody that blocks the activation of PC and prevents the engagement of APC with its cellular 
receptors [13].   Abrogation of APC activity attenuated EAE severity, and we attributed the 
attenuation of disease to the increased expansion and activation of CD11b
+
 myeloid cells, 
particularly the suppressive MDSC subset, which was capable of suppressing the responses of 
effector T-cells required for disease progression.  Inhibition of APC during EAE, additionally, 
resulted in increased BBB permeability, as evidenced by pronounced leukocyte infiltration in the 
brains of anti-PC mice.  However, despite the considerable presence of cellular infiltrates in the 
brains of anti-PC mice, we observed decreased inflammatory and pathogenic conditions in the 
CNS of these mice.  We notably observed that the pathogenic cytokines produced by 
encephalitogenic CD4
+
 T-cell subsets are decreased in the CNS; whereas the frequency of the 
anti-inflammatory T-reg subset is increased, both in the CNS and in the periphery of anti-PC 
mice.  We hypothesize that the decrease in encephalitogenic CD4+ T-cells and the increase of 
the T-reg subset is a result of the expansion of CD11b
+
 MDSCs in anti-PC mice.  This was 
directly confirmed by demonstrating that the co-culture of isolated CD11b
+
 cells from anti-PC 
mice resulted in the suppression of MOG35-55-induced CD4
+
 T-cell proliferation and additionally 
resulted in the increase of T-reg frequency.  Overall, we conclude that inhibition of APC during 
EAE affected disease pathogenesis at multiple fronts, specifically increasing BBB permeability 
and concurrently modulating leukocyte frequency and functional responses, resulting in an 
increased and more activated CD11b
+
 myeloid population, including the suppressive MDSC 
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subset, which subsequently suppressed effector T-cells required for disease progression.  
Therefore, the net effect of APC inhibition during EAE is attenuated disease progression. 
We speculate that the increase of CD11b+ myeloid cells in anti-PC during EAE 
progression is a direct consequence of APC inhibition.  This hypothesis is based on a recent 
study demonstrating that APC is an effective suppressor of the pro-inflammatory responses of 
CD11b
+
 myeloid cells through direct engagement with the CD11b integrin [14].  Thus, it is 
likely that abrogated APC activity in the EAE inflammatory setting can result in an increased 
expansion and activation of the CD11b
+
 myeloid population, including the suppressive, CD11b
+
 
MDSC subset.  MDSCs are observed to expand in various inflammatory and pathogenic settings 
[15-17], and the expansion and suppressive capabilities of these cells have been demonstrated to 
be mediated by Stat3 [18, 19].  We hypothesize that APC acts as a direct negative regulator of 
MDSCs, thus decreased APC activity can result in the greater expansion and activation of 
MDSC in inflammatory settings.  This hypothesis is supported in a study by Cao et. al, wherein it 
was demonstrated that APC can specifically downregulate the expression of Stat3 in CD11b
+
 
myeloid cells through interactions with the CD11b integrin and subsequent PAR-1 activation 
[14].  Moreover, we have shown that APC directly binds MDSCs, and we have confirmed that 
MDSCs express both CD11b and PAR-1, suggesting that these cells are potentially responsive to 
APC regulation.  However, we have yet to demonstrate that APC can directly regulate the 
cellular processes of MDSCs, and we, therefore, want to confirm this in a future study.  We 
specifically want to determine if APC can inhibit the expression and/or activation of Stat3 in 
MDSCs; this will directly implicate APC in the regulation of MDSC expansion.  The suppressive 
capability of MDSCs on T-cells is mediated through one or a combination of Arg I activity, 
iNOS expression, and ROS generation.  We observed elevated levels of all three factors in 
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MDSCs as a result of APC inhibition.  In a future study, we, therefore, also want to confirm 
whether APC can directly inhibit Arg I activity and the generation of NO and ROS in MDSCs.  
One specific experiment we want to carry out is to isolate CD11b+ cells from anti-PC mice, and 
assess whether treatment with exogenous APC results in the decrease of Stat3 expression and/or 
Stat3 activation, as well as inhibition of Arg I activity, iNOS expression, and ROS generation. 
We have attributed the attenuation of EAE severity in anti-PC mice to a defective and 
deficient effector CD4
+
 T-cell population as a result of increased expansion of the suppressive 
MDSC subset.  We observed significantly decreased CD4
+
 T-cells in the periphery of anti-PC 
mice compared to controls, and we additionally observed lowered cell surface CD3 expression, 
which may potentially have resulted in an overall lowered T-cell activation.  Consistently, we 
observed that there is decreased pathogenic cytokines associated with encephalotogenic CD4+ T-
cell subsets in the CNS of anti-PC mice.  Furthermore, we detected significantly increased 
frequency of T-regs both in the CNS and in the periphery in anti-PC mice, likely contributing to 
attenuated EAE pathogenesis.  We postulated that the deficient and defective CD4
+
 T-cell subset 
is a result of the increased and more activated MDSCs, which are potent T-cell suppressors.  The 
production of Arg I, NO, and/or ROS by MDSCs, all of which are increased in MDSCs in anti-
PC mice, suppresses antigen-induced proliferation of T-cells [17, 20-23].  Arg I and ROS are 
additionally known to downregulate the expression of CD3ζ, resulting in the downregulation of 
the T-cell receptor complex (TCR) and lowered T-cell activation [21].  Moreover, MDSCs have 
also been directly implicated in the expansion of T-regs [24, 25].  Since EAE progression and 
disease pathogenesis are primarily mediated by CD4
+
 T-cells [26, 27], we hypothesize that the 
decreased and defective effector CD4
+
 T-cell population, coupled with the shift towards an 
increase in the T-reg subset is the primary cause for the attenuated EAE severity observed in 
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anti-PC mice.  To confirm whether the CD4
+
 T-cell population from anti-PC mice are incapable 
of mediating EAE progression and are thus responsible for the decreased EAE severity in anti-
PC mice, a future experiment that we want to carry out is to isolate CD4
+
 T-cells from anti-PC 
and control mice and adoptively transfer these cells into recipient mice that lack endogenous 
CD4
+
 T-cells.   We can then monitor and assess EAE progression in the recipient mice that 
received CD4
+
 T-cells from either donor groups.  If the CD4
+
 T-cells from the donor anti-PC 
mice are inherently defective in inducing EAE, we expect that the recipient mice that received 
these cells will develop less severe EAE relative to recipient mice that received CD4
+
 T-cells 
from control mice. 
We strategically administered anti-PC antibody on days 0, 2, 4, and 6 post EAE induction 
to inhibit APC during the induction phase of EAE, which encompasses the peripheral activation 
of leukocytes after MOG35-55 immunization.  Administration of anti-PC antibody within this 
timeframe also abrogates APC activity at the outset of the effector phase of EAE, which is 
characterized by leukocyte infiltration into the CNS, typically starting at around day 5 post EAE 
induction [28].  Thus, we inhibited APC during two phases of EAE progression, and consistently 
the effects of APC inhibition was observed in both stages of EAE.  Specifically, we hypothesize 
that APC inhibition during the induction stage of EAE led to the increase in MDSCs and the 
consequent suppression of T-cell responses.  We also postulate that inhibition of APC resulted in 
increased BBB permeability, leading to the pronounced leukocyte infiltration in the brain as EAE 
proceeded to the effector stage of the disease.  We believe that these multiple effects of APC 
inhibition on various components of EAE pathogenesis have conflicting influences on the overall 
EAE progression, but, ultimately, the net effect is attenuated EAE.   In a future study, we want to 
alter the timeframe of APC inhibition to determine if abrogation of APC activity during different 
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stages of EAE progression can have varying effects on EAE pathogenesis.  An alternate anti-PC 
treatment, for instance, is to administer the antibody during the peak of the effector phase of 
EAE (days 12 – 18 post EAE induction).  Treatment with anti-PC within this timeframe will 
inhibit APC activity specifically during the effector phase, while the influence of APC inhibition 
on the induction stage of EAE is minimized.  Therefore, the complexity of abrogating APC 
during multiple stages of EAE, which resulted in the conflicting influences on disease 
progression is eschewed.  We anticipate that limiting APC activity within the effector stage of 
EAE would predominantly increase the infiltration of leukocytes in the brain, as a consequence 
of increased BBB permeability and dysfunction, thus leading to increased EAE severity. 
The increased BBB permeability observed in anti-PC mice as a result of APC inhibition 
is consistent with the well-established cytoprotective effects of APC on endothelial cells [29, 
30].  APC is known to confer vascular barrier protection resulting in decreased leukocyte 
extravasation into tissues during pathological settings [31, 32].  APC mediates cell signaling in 
endothelial cells through interactions with EPCR and PAR-1 expressed on endothelial cells, 
resulting in an overall enhancement of vascular barrier protection through increased expression 
of endothelial junctional proteins that mediate the connectivity of endothelial cells [4, 29, 33, 
34].  Moreover, APC signaling is also known to induce endothelial cells to downregulate cellular 
adhesion molecules, which facilitate the rolling, firm adhesion and the subsequent 
transendothelial migration of leukocytes [35].  It should also be noted that APC’s protective 
effects on vascular barriers have been observed in several disease conditions and pathological 
settings [4, 35].  BBB dysfunction is one of the hallmark pathogenesis of EAE and MS, which is 
induced in EAE by pertussis toxin (PTX) administration combined with increased production of 
pro-inflammatory factors both in the CNS and systemically [10, 11, 27, 36, 37].  We postulate 
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that decreased APC in the circulation of anti-PC mice further increases the susceptibility of the 
BBB to the effects of PTX and inflammatory factors, thus resulting in increased permissiveness 
to leukocyte extravasation, potentially even to non-encephatologenic and naive leukocyte 
populations, which would explain the minimized pathogenic conditions in the CNS of anti-PC 
mice despite the pronounced presence of leukocyte infiltrates.  In a future study, we want to 
assess the phenotype of the BBB in anti-PC mice.  We specifically want to determine if APC 
inhibition during EAE can alter the BBB’s expression of adhesion molecules and endothelial 
junctional proteins.    
The primary function of APC as an anti-coagulant is to inhibit the further production of 
thrombin, which serves as the central enzyme of the coagulation cascade [38].  Therefore, it is 
probable that inhibition of APC during EAE progression not only modulated the immune 
response but also potentially affected the coagulation response.  Several studies have detected the 
elevation of thrombin activation in the course of EAE progression [8, 9].  With APC inhibition, it 
is likely that thrombin is further elevated during EAE.  We want to confirm in a future study 
whether there is increased thrombin in the circulation of anti-PC mice compared to controls 
during EAE.        
   If thrombin is increased in anti-PC mice as a result of APC inhibition, it is likely that 
the increase in thrombin activity can be a contributing factor in the pathogenesis that we have 
observed in anti-PC mice, notably the increase in BBB permeability.  APC and thrombin are 
functionally opposite, both in their respective roles in the coagulation process and their influence 
on the immune response [38].  Their effects on vascular barrier permeability are polar opposites; 
thrombin activity results in increased vascular barrier disruption while APC enhances vascular 
barrier stability [29, 39].  We hypothesize that elevation of thrombin in EAE can contribute to 
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BBB dysfunction in EAE, and potentially in MS.  In fact, we have demonstrated that thrombin 
effectively induces an inflammatory phenotype in an in vitro human BBB.  Thrombin treatment 
of human brain endothelial cells resulted in significantly increased expression of cell adhesion 
molecules, ICAM-1 and VCAM-1.  Both adhesion molecules have been implicated in leukocyte 
transmigration across the BBB in EAE and MS [40, 41].  We observed significantly increased 
mRNA expression of both adhesion molecules in brain endothelial cells even at low thrombin 
treatment (0.5 – 5 U/ml), suggesting that the BBB is highly responsive to thrombin activation.  
Thrombin additionally induced brain endothelial cells to secrete various chemokines from 
different chemokine families.  A number of these chemokines have been implicated in EAE and 
MS pathology; notably the neutrophil chemoattractant, CXCL8, which has been detected in the 
CSF of MS patients, as well as CCL2, a potent chemoattractant for monocytes and have been 
suggested to be involved in EAE progression [42].  Furthermore, we observed that thrombin 
effectively increased the paracellular permeability of the BBB, evidenced by lowered 
transendothelial electrical resistance (TEER), and increased permeability to dextran molecules.  
Overall, the collective effects of thrombin on the BBB resulted in the induction of an 
inflammatory phenotype that can potentially facilitate the recruitment, firm adhesion, and 
diapedesis of leukocytes.  In neuroinflammatory settings, such as in EAE or MS, we postulate 
that elevated thrombin levels in the systemic circulation can be a contributing factor to leukocyte 
extravasation into the CNS.  As previously mentioned, several studies have detected that 
thrombin is elevated in the course of EAE progression, and our study has provided a potential 
mechanism through which thrombin can influence EAE pathogenesis.    
Overall, we have shown that APC and thrombin, the major factors of the coagulation 
system, are effective modulators of EAE pathogenesis.   We have demonstrated that thrombin 
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can directly regulate the BBB phenotype, which plays a prominent role in EAE and MS 
pathology.  Additionally we have shown that alteration of APC levels in the circulation during 
EAE progression affects BBB permeability as well as the functional responses of leukocytes, 
demonstrating that APC can modulate EAE pathogenesis at multiple fronts.  It should be noted 
that inhibition of APC, generally known as anti-inflammatory molecule, unexpectedly resulted in 
alleviated EAE, further highlighting the complexity of APC’s multi-leveled influence on 
inflammatory conditions.  Therefore, it has to be taken into account that while the broad-ranging 
influence of APC and thrombin on pathological conditions makes them attractive targets in 
therapeutic avenues, our study shows that it is the pleiotropic nature of these coagulation 
components that also makes it difficult to accurately extrapolate their global effects in each 
unique disease setting.  In assessing the potential of thrombin and APC as therapeutic targets, 
their multi-faceted influence on various areas of the pathogenic setting need to be carefully 
considered; keeping in mind that each of thrombin’s and APC’s effects on individual 
components of the disease pathogenesis may have separate and, at times, opposing influence on 
the overall disease progression.  
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APPENDIX-A 
Percentage of anti-PC mice with considerable infiltrates in brain  
despite attenuated EAE
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        IgG Control     Anti-PC 
Severe CNS infiltration with 
clinical symptoms (Day 14-17) 
  
          62.5 %      16.6 % 
Severe CNS infiltration with 
no clinical symptoms (Day 14-
17) 
  
            0 %      33.3 % 
No CNS infiltration with no 
clinical symptoms (Day 14 – 
17) 
           37.5 %       50 % 
      
Appendix-A.   Anti-PC mice exhibit considerable infiltration in the brain despite attenuated 
symptoms.  
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APPENDIX-B 
Frequency of cellular infiltrates in the brains of anti-PC and 
control mice 
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Appendix-B.  Anti-PC and IgG Control mice exhibit comparable frequency in various 
infiltrating leukocyte populations in the CNS.  Cellular infiltrates from the brains of anti-
PC and control mice were isolated by percoll gradient, and cells were subjected to flow 
cytometry to assess the frequency of A) CD48+ T-cells, B) CD8+ CD11c+ cells, C) 
CD11b+F480+ cells, and D) B220+ cells.  Data are represented as means + SEM. 
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APPENDIX-C 
Expression of various cell surface markers on splenic CD4
+
 T-cells from 
control and anti-PC mice 
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